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 Overexpression of tumor-derived mutant p53 is a common event in 
tumorigenesis, suggesting an advantageous selective pressure in cancer initiation and 
progression. Given that p53 is found to be mutated in 50% of all human cancers, 
restoration of mutant p53 to its wild type biological function has been a widely sought 
after avenue for cancer therapy. Most research efforts have largely focused on restoration 
of mutant p53 by artificial means given that p53 has some degree of conformational 
flexibility allowing for introduction of short peptides and artificial compounds. Recently, 
theoretical modeling and studies focused on restoration of mutant p53 by physiological 
means has raised the question of whether there are effective therapies worth exploring 
that focus on global physiological mechanisms of restoration of p53. Herein, we provide 
computational analysis of the thermodynamic stabilities of both wild-type and mutant p53 
 
 ii 
core domains by studying their respective minimum potential energies. Also, it is widely 
accepted that wild type p53 is modulated by various acetyl transferases as well as 
deactylases, but whether this mechanism of p53 modulation can be exploited for 
physiological restoration of mutant p53 remains under intense investigation. Using 
prostate cancer cell lines representative of varying stages of aggressiveness as a model, 
we show that ID4 dependent acetylation promotes mutant p53 DNA-binding capabilities 
to its wild type consensus sequence, thus regulating p53-dependent target genes leading 
to subsequent cell cycle arrest and apoptosis. Specifically, we identify that ID4 promotes 
acetylation of K373 and to a lesser extent K320, in turn regulating p53-dependent 
biological activities. Together, our data provides computational analysis of the core 
domain of certain mutant forms of p53 and a molecular understanding of ID4 dependent 
acetylation that suggests a strategy of enhancing p53 acetylation at sites K373 and K320, 
critical sites of post translational modification of p53, that may serve as a viable 

















SUBMITTED TO THE FACULTY OF CLARK ATLANTA UNIVERSITY 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR 
















































 I would first like to express my special appreciation to my Lord and Savior, Jesus 
Christ.  It is truly through the indwelling spirit of Christ, in me that I have come to the 
fulfillment of this phase of my academic and doctoral journey.  I would like to thank my 
mentor, Dr. Jaideep Chaudhary, for encouraging my research and allowing me to grow as 
a research scientist. His advice, both professional and personal, has been vital to my 
success, and I am truly grateful for the experience and the knowledge he has imparted to 
me. I would also like to thank my committee members: Drs. Nathan Bowen, Valerie 
Marah, Myron Williams, and Cimona Hinton. Their constructive criticism, comments, 
and suggestions will never be forgotten.  
Additionally, I am thankful to all members of Dr. Chaudhary’s laboratory, both 
current and former graduate students, and to the faculty and staff in the Department of 
Biological Sciences. Their support in my research, as well as their involvement in the 
many collaborative projects, has given me first-hand knowledge of the importance of 
collaboration to the scientific process. Also, my research was funded by NIH grant 
#R01CA128914 and Title III.  Finally, I would like to express appreciation to my beloved 
family for their unending love and support. They have pushed me in some of my most 
challenging moments, and I am forever grateful for them. Words cannot express how 
grateful I am to my parents, Joel, my grandparents, my brothers, sisters, and all of my 
relatives and close friends. Your prayers for me were what sustained me thus far. 
 iv 
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS ............................................................................................... iii 
LIST OF FIGURES ......................................................................................................... viii 
LIST OF TABLES ...............................................................................................................x 
LIST OF ABBREVIATIONS ............................................................................................ xi 
CHAPTER  
I. INTRODUCTION ...............................................................................................1    
II. LITERATURE REVIEW ..................................................................................10 
2.1 Prostate and Prostate Cancer .......................................................................10         
2.1.1 Androgen and Androgen Receptor (AR) ...............................................13 
2.1.2 Molecular Mechanisms of Prostate Cancer ...........................................14 
2.1.3 Genetic Disposition in Prostate Cancer Progression .............................15  
2.2 Tumor Suppressor p53 “Guardian of the Genome” ....................................16 
2.2.1 p53 and Cell Cycle ................................................................................17 
2.2.2 p53 and Apoptosis .................................................................................17 
2.2.3 Acetylation of p53 .................................................................................19 
2.3 p53 and Cancer ............................................................................................21 
2.3.1 p53 Mutations ........................................................................................21 
2.3.2 Gain-of-function Mutant p53 ................................................................22 
2.4 Mechanisms of Mutant p53 Function ..........................................................23 
2.4.1 Mutant p53 Binds to DNA to Alter Gene Expression ...........................23 
2.4.2 Mutant p53 Binds to Transcription Factors ...........................................23 




2.4.4 Stability of Mutant p53 ..........................................................................25 
2.4.5 Animal Models for Mutant p53 GOF ....................................................26 
2.4.6 Mutant p53: Different in the Same Way? .............................................27 
2.5 Therapeutic Applications of p53 .................................................................28 
2.6 ID4-p53 Cross-talk ......................................................................................29 
2.7 Molecular Dynamic Studies of p53 .............................................................30 
2.8 Conclusion ...................................................................................................34 
2.9 ID Function, Sequence and Structural Properties .......................................34 
2.10 The Role of ID4 during Development and Differentiation .......................36 
2.11 ID Knockout Mouse Models .....................................................................38 
2.11.1 Global ID4 Knockout Model ...............................................................38 
2.11.2 ID4 and Neuronal Development ..........................................................39 
2.11.3 ID4 and Mammary Gland Morphogenesis ..........................................39 
 2.11.4 ID4 and Spermatogenesis ....................................................................39 
2.11.5 ID4 and Osteoporosis ..........................................................................40 
2.11.6 ID4 and Prostate ..................................................................................40 
2.12 ID4 and Cancer ..........................................................................................41 
2.12.1 ID4 as a Tumor Promoter ....................................................................42 
2.12.2 Breast Cancer ......................................................................................42 
2.12.3 Other Cancers ......................................................................................43 
2.12.4 ID4 DNA Alterations ..........................................................................44 





  2.12.6 ID4 and Prostate Cancer ......................................................................44   
2.12.7 ID4 in Prognosis and Survival .............................................................46   
2.12.8 ID4 and Angiogenesis .........................................................................46  
2.12.9 ID4 and Chemo-resistance ..................................................................47  
2.13 Regulation of ID4 Gene Expression ..........................................................48 
2.13.1 Transcriptional Regulation ..................................................................48  
2.13.2 Epigenetic Regulation .........................................................................50  
2.13.3 Regulation of ID4 Expression by MicroRNA  ....................................52  
2.14 Mechanism of Action of ID4.....................................................................52  
2.15 The Role of ID4 in Cell Cycle and Proliferation.......................................54 
2.16 ID4 in Therapeutics ...................................................................................55   
2.17 Conclusion .................................................................................................55 
III. MATERIALS AND METHODS ............................................................................ 57 
IV. RESULTS ................................................................................................................... 68 
4.1 ID4 Regulates Wild-type and Mutant p53  ..................................................... 68 
4.1.1 Expression of ID4 in Prostate Cancer Cell Lines ..................................68 
4.2 ID4 Effects on Proliferation and Gene Profile upon Silencing of ID4  
      in LNCaP Cells  ...........................................................................................71 
4.3 ID4 Effects on p53-mediated Apoptosis .....................................................72 
 
4.3.1 ID4 Promotes p53-mediated UV-Induced Apoptosis  ..........................78 
 





4.5 ID4 Regulates p53 Regulatory Mechanisms: p14ARF-MDM2 
 
  Interaction .......................................................................................................... 82 
 
4.6 ID4 Restores Mutant p53 DNA Binding and Transcriptional Activity.......83 
 
4.7 ID4 Recruits CBP/p300 to Promote p53 Acetylation  ................................88 
 
4.8 Molecular Dynamics Studies: Mutations in p53 .........................................94 
 
4.8.1 Solvation ................................................................................................99 
 
V. DISCUSSION .......................................................................................................... 101 
5.1 Loss of ID4 Promotes Tumorigenecity of Prostate Cancer Cells .............101 
5.2 ID4 Regulates Wild-type and Mut-p53 Biological Activity .....................101 
5.3 ID4 Dependent Acetylation Restores Mutant p53 DNA Binding and 
 Transcriptional Activity ...........................................................................102 
5.4 Molecular Dynamic Simulation of Mut-p53 is Predictive and 
       Correlative ................................................................................................108 






LIST OF FIGURES 
 Figure                                     
1.  ID4 expression in cancers  ..........................................................................................5 
2.  Relation between p53 mutation and ID4 expression in breast cancer obtained  
 from TCGA provisional dataset ...............................................................................7 
3.  The adult prostate and surrounding structures  ........................................................11 
4.   p53 pathway, depicting p53 regulatory network  ....................................................19 
5.   The acetylation of p53 stimulates its sequence-specific DNA-binding  .................20 
6.    Protein sequence alignment of the four known human ID proteins .......................34 
7.    ID4 expression profile from The Cancer Genome Atlas database  ........................43 
8.    ID4 silencing and wild type and mutant p53 overexpression model  ....................69 
9.    Silencing of ID4 and wild type and mutant p53 overexpression profile  ...............70 
10. Loss of ID4 promotes proliferation .......................................................................72 
11. Gene expression profile following ID4 silencing and wild type and mutant p53  
 overexpression in PC3 cells ...................................................................................74 
12. ID4 promotes p53-mediated apoptosis ..................................................................77 
13. ID4 promotes p53-mediated apoptosis via UV-radiation ......................................79 






15. ID4 regulated p53 via p14ARF and MDM2 interaction ........................................83 
16. ID4 restores mutant p53 DNA binding and Transcriptional Activity  (LNCaP        
 and DU145 cells) ...................................................................................................86 
17. ID4 restores mutant p53 DNA binding and Transcriptional Activity in PC3  
 cells  .......................................................................................................................87 
18. Acetylation of p53 and interaction with CBP/p300 and ID4 .................................92 
19. ID4 promotes p53-R175H transcriptional activity and apoptosis .........................93 
20. Difference in calculated energy between mutated and wild type p53  ..................94 
21. Approximation (μ) factor of mutant p53 ...................................................... 96 
22. Wild type and mutant p53 simulated in a box of water .......................................100 







LIST OF TABLES 
 
Table                                                                                                               
1. qRT-PCR and ChIP Primers Used in the Study  ........................................................ 58 
2. Antibodies Used for Immunoblots and Immunocytochemistry, and ChIP  ........... 59 
3. ID4 Silencing and Wild-type and Mutant p53 Overexpression Model ................... 69 
4. Calculated Energy Based on Simulated Annealing Method  ................................... 94 
5. Calculated Energy Based on Simulated Annealing Method: R248Q Mutant  ....... 94 
6. Calculation of , a Dimensionless Approximation Entity for p53 Mutants ........... 97 
7. Results for More Mutations in p53 Based on our Approximation .......................... 98 
8. The Overall Frequency of Mutations in Cancer and 𝜇 Factor (Approximation) ... 99 
9. The Calculated Energy of Solvation and the Vacuum for the Wild-type and  







LIST OF ABBREVIATIONS 
ANOVA ............................................................................................... Analysis of Variance 
AR .......................................................................................................... Androgen Receptor 
BCS ......................................................................................................... Bovine Calf Serum 
bp............................................................................................................................ Base Pair 
BPH ......................................................................................... Benign Prostatic Hyperplasia 
BMP ........................................................................................ Bone Morphogenetic protein 
BRCA1 ......................................................................................................... Breast Cancer 1 
BSA ................................................................................................. Bovine Serum Albumin 
cDNA .................................................................... Complementary Deoxyribonucleic Acid 
ChIP ................................................................................ Chromatin Immunnoprecipatation 
CRPC .......................................................................... Castration Resistant Prostate Cancer 
Ct .................................................................................................................. Cycle threshold 
DAPI ................................................................................... 4'-6-Diamidino-2-phenylindole 
DNA ................................................................................................. Deoxyribonucleic Acid 
dNTP ........................................................................................... Dinucleotide Triphosphate 





EGF ......................................................................................... Epidermal Growth Factor 
EMSA .................................................................... Electrophoretic Mobility Shift Assay 
ER ........................................................................................................ Estrogen Receptor 
FBS ....................................................................................................Fetal Bovine Serum 
HLH ...................................................................................................... Helix Loop Helix 
ICC ................................................................................................. Immunocytochemisty   
ID ........................................................................................... Inhibitor of Differentiation 
MDM2 ........................................................................................ Murine double minute 2 
MMP ......................................................................................... Matrix Metalloproteinase 
MMP ......................................................................... Mitochondrial Membrane Potential 
mRNA ................................................................................ Messenger Ribonucleic Acid 
MS-PCR ............................................ Methylation Specific-Polymerase Chain Reaction 
PBS ......................................................................................... Phosphate Buffered Saline 
PCa .......................................................................................................... Prostate Cancer 
PCR ...................................................................................... Polymerase Chain Reaction 
PIN .............................................................................. Prostatic-Intraepithelial Neoplasia 
PSA ........................................................................................... Prostate Specific Antigen 
PVDF ....................................................................................... Polyvinylidene Difluoride 
RT .................................................................................................. Reverse Transcriptase 
RT-PCR ........................................................... Reverse Transcription Polymerase Chain 
RNA ...................................................................................................... Ribonucleic Acid 







The presence of p53 missense mutations is an overwhelming characteristic and 
likely critical step in the oncogenic process, usually as a result of somatic mutations, 
which occur in approximately half of all human cancers and constitute a cornerstone in 
tumorigenesis. As reviewed in Oren et al.1 in principle, emergence of a p53 mutation 
within a cell might have three, not mutually exclusive, types of outcomes.1 First, such 
mutation is expected to abrogate the tumor suppressor function of the affected TP53 
allele, reducing the overall capacity of the cell to mount a proper p53 response; if both 
alleles eventually become mutated, or if the remaining allele is lost, such cells will be 
totally deprived of anticancer protection by p53.2 Second, many common mutant p53 
isoforms can exert dominant–negative effects over coexpressed wild type p53, largely by 
forming mixed tetramers that are incapable of DNA binding and transactivation. Hence, 
even if one wild-type allele is retained, the cell may be rendered practically devoid of 
wild type p53 function through such mechanism, particularly if the mutant protein is 
expressed in excess over its wild type counterpart.3 Third, and most relevant, the 
emergent mutant p53 protein possess activities of its own, often not present in the 
original wild type p53 protein, which can actively contribute to various aspects of tumor 
progression.4 These new abilities attributed to mutant p53 are commonly referred to as 






have mainly been classified into two main categories: type I mutations, which affect 
amino residues directly involved in the DNA interaction (R248H, V274F, and R273H), 
and class II mutations involving residues responsible for the stabilization of the three-
dimensional structure of p53.5 Structural mutants, includes the majority of p53 proteins 
found in human tumors, such as R175H, P223L, R249H, and R282H mutants, all of 
which destabilize p53 conformation and the p53 DNA-binding.  
 Numerous studies of mutant p53 have been designed to explore restoration of 
DNA-binding capability artificially by site-specific phosphorylation and amino acid 
substitution primarily in the c-terminus of p53 to resemble wild type p53.6 Theoretical 
modeling of p53 has also been central to understanding the DNA-binding capabilities of 
mutant p53, as well as conformation changes induced by protein-protein interactions, as 
well as a number of artificial compounds have been identified that can reactivate mutant 
p53 by directly stabilizing the interaction with DNA and/or by preventing misfolding or 
aggregation. Similarly, the structure of wild-type p53 itself naturally comprises unfolded 
regions and displays high tendency to aggregation.7 Several of these reactivating agents 
include: CP-31398, 8 ellipticine,9 MIRA-1,10 RITA,11 and PRIMA-1.12 Lastly, 
reactivating molecules represented by short peptides introduced in the c-terminal domain 
of p53, when introduced into tumor cells harboring p53 mutants, lead to induction of p53-
regulated genes and apoptosis.13 In this case, however, the mechanisms of activation are 






 Moreover, interestingly, studies have shown that the p53 mutations are indeed 
not all functionally equivalent.4 It’s widely been reported that mutations in the DNA-
contacting residues of p53 have a less dramatic effect on the folding of the p53 protein 
than the structural mutants.14 On the other hand, mutant p53 can engage in protein–
protein interactions with a growing number of transcription factors, often being recruited 
to binding sites of those factors on chromatin, and modulate their transcriptional output 
both positively and negatively.15 In fact, very early studies showed that certain p53 
mutants retain the ability to activate transcription of genes known to be regulated by 
wild-type p53 and to induce cell cycle arrest or apoptosis in some cell types but not in 
others providing a physiologically relevant basis for study of mutant p53 restoration to 
wild type biological activity by non-artificial means.  
Our laboratory as well as other groups have shown that in the case of wild type 
and mutant forms of p53, the interaction with acetylases and acetylation of p53 itself is 
indispensible in regulation of DNA binding capabilities and transcription activation 
potential, as well as the ability of p53 to trigger cell cycle arrest or apoptosis.7a, 16 In a 
previous study done by our laboratory we provide evidence that ID4, a transcriptional 
regulator could recruit CBP/p300 to promote large macromolecular assembly on p53 that 
could result in its acetylation and increased biological activity. Here, we demonstrate that 
ID4, a transcriptional regulator can promote p53-dependent induced cellular death and 
cell cycle arrest in prostate cancer cells by specifically modifying the acetylation pattern 
of p53, which increases its transcriptional activity and promotes the expression of pro-






we identify lysines 373 and 320 as critical acetylation sites that aid in p53 biological 
activities. Together, the results presented herein suggest that ID4 dependent p53 
acetylation can be used as model to revert mutant p53 to wild type biological activity. 
ID proteins (ID1, ID2, ID3 and ID4) are dominant negative transcriptional 
regulators of basic Helix Loop Helix (bHLH) transcription factors that lack the basic 
DNA binding domain but have intact HLH domain.17 Thus, ID proteins can interact with 
bHLH proteins but the heterodimer fails to bind DNA and activate E-Box dependent 
transcription of target genes.  ID proteins regulate the function of various ubiquitously 
expressed and tissue specific bHLH transcription factors as well as many non-bHLH 
proteins with different affinities18 in complex transcriptional networks.17, 19 Herein, we 
focus on the current understanding of ID4 in development and disease. 
The de-regulation of ID proteins contributes to developmental defects and 
neoplastic progression. Based on significant sequence homology of ID protein sub-types 
within the HLH domain, a degree of functional redundancy is expected at least in their 
interaction with bHLH transcription factors. However, recent studies suggest that each of 
the ID sub-type also participates/regulates unique biological activities which is evident 
from non-compensatory phenotypes in ID specific knockout models and preferred protein 
interactions, both bHLH and non-bHLH. In this context Inhibitor of differentiation/DNA-
binding 4 (ID4) has emerged as an outlier in terms of expression and function. Evidence 
from animal models indicates that phenotypic changes and molecular pathways regulated 
by ID1, ID2 and ID3, in general are not similar to those regulated by ID4.  The opposing 






dominant negative bHLH transcriptional regulators may be just a fraction of their 
overall function. The majority of ID sub-type specific function could involve unknown 
and perhaps yet undefined interactions with sequence specific bHLH or non-bHLH 
proteins resulting in non-overlapping biological endpoints.20 
 As key regulators of cell cycle and differentiation, ID proteins have shown a vast 
regulatory function across diverse cellular functions, including cell cycle, apoptosis, 
senescence and cancer.20 
ID4 appears to act primarily as a tumor suppressor in most cancers as opposed to 
ID1, ID2 and ID4, which in most cases acts as tumor-promoters or supporting 
oncogenes.17, 21 In a small subset of cancers, ID4 also acts as a tumor promoter (Figure 1).  
Beyond correlative studies showing ID4 expression in tumors, the underlying molecular 
mechanism remains largely unexplored.   
 
Figure 1. ID4 expression in cancers. A: ID4 expression profile in various cancers from the Oncomine 
database. The blue and red boxes represent cancers in which ID4 expression is decreased or increased 
respectively as compared to normal counterparts. B: The ID4 expression in various cancers from literature 
mining .The green lines point to cancers in which ID4 is down-regulated whereas red lines point to cancers 







In general, the expression of ID proteins (ID1-ID3) is high in proliferating 
cells.19c, 19d Their expression is down regulated during differentiation.22 Consistent with 
these observations the expression of ID1, ID2 and ID3 proteins is increasingly observed 
in many cancers and, in most cases, associated with aggressiveness of the disease 
including poor prognosis, metastasis, and angiogenesis.21 In contrast, the expression of 
ID4 decreases in many cancers.23 Of all the four ID proteins, the underlying mechanism 
of ID1, ID2 and, to a lesser extent, ID3 in cancer is relatively well known.24 ID1, ID2 and 
ID3 have been shown to negatively regulate the expression of Cyclin D1, p16 and p21, 
but promote the expression of matrix metalloproteinase (MMPs)24-25 and thus, promote 
aggressiveness of disease. On the contrary, large numbers of studies have reported 
reduced ID4 expression due to promoter hyper-methylation during cancer progression to 
a more malignant phenotype.26 
ID4 is required for normal prostate morphogenesis where it is specifically 
expressed in the luminal epithelial cells.26b Prostates from ID4-/- mice exhibit decreased 
branching morphogenesis and often display prostatic intra-epithelial neoplastic lesions 
(PIN).27 Loss of ID4 expression is also frequently observed in prostate cancer, suggesting 
its essential role as a tumor suppressor.28 Knockdown of ID4 in LNCaP prostate cancer 
cell lines results in aggressive growth, increased cell survival and acquisition of 
castration resistance phenotype usually associated with advanced disease.29 In addition to 
prostate cancer, decreased ID4 expression is also observed in leukemia,30 AML,31 CLL,32 
ALL,33 glial neoplasia,34 squamous cell carcinoma,35 gastric cancer,36 pancreatic cancer,37 






esophagus and esophageal adenocarcinoma40 and lung cancer.41 Thus, epigenetic 
inactivation of ID4 due to promoter methylation appears to be the key mechanism in 
many cancers. ID4 is also overexpressed in a small subset of cancers, which will be 
discussed herein.  
Previous studies have explored possible correlations between ID4 and p53. A 
negative correlation was observed between mutant p53 and ID4 expression in meta-
analysis of clinical studies.42 Similarly, in the TCGA dataset (Breast Invasive Carcinoma, 
TCGA Provisional), p53 mutations were observed in 32% of cases (306 cases out of 956) 
whereas ID4 was altered in only 3% cases. Interestingly, ID4 expression was altered in 
only 6% of cases in which p53 was mutated. Hence a significant correlation was not 
observed between p53 mutations and ID4 expression (Figure 2). However, previous 
studies from our laboratory in prostate cancer found that ID4 was modulating wild type 













Figure 2. Relation between p53mutations and ID4 expression in breast cancer obtained from TCGA 
provisional dataset (cBIO Portal). A total of 956 samples were analyzed of which 306 (32% demonstrated 
p53 mutations (green) and 3% demonstrated ID4 alterations (red bars: up-regulated, blue bars: down-
regulated)). Only 20 samples with p53 mutations showed alterations in ID4 expression. The figure only 
shows the samples with p53mutations and ID4 expression. The grey bars represent samples with no change 
in either p53 (mutations/ expression) or ID4 (expression) (majority of these samples not shown). The 






The molecular mechanisms by which mutant p53 may function have been 
reviewed extensively.4 These pathways include alterations in the DNA-binding ability of 
mutant p53, interaction of mutant p53 with other proteins, including transcription factors 
or proteins not directly related to the regulation of gene expression. It is clear that the 
effects of mutant p53 are strongly context dependent, and interactions that promote 
activity in some circumstances may be inhibitory in others. 
Previous studies from our laboratory have demonstrated that ID4 promotes 
transcriptional activity of wild type p53 in a CBP/p300 dependent acetylation at K320 
and K373 residues.43 Interestingly, ID4 also restores the wild type transcriptional activity 
of mutant p53 in DU145 cells through a similar mechanism. The restoration of mutant 
p53 transcriptional activity in DU145 is evident that ectopic ID4 promotes apoptosis, 
attenuates cell cycle and promotes senescence in these cells 44 in spite of mutations in Rb 
and p16.45 Moreover, electrophoretic shift assays (EMSA) and chromatin 
immunoprecipation (ChIP) analysis demonstrated that ID4 promotes binding of mutant 
p53 to the consensus wild type p53 DNA response element and enrichment to p53 
binding sites on p21, BAX and PUMA promoters. Co-elution of ID4 as part of the p53-
CBP/p300 complex with p53 antibody and co-elution of p53 with ID4 antibody suggest 
that ID4 can recruit CBP/P300 on wild type and mutant p53 to promote acetylation.43 
Whether ID4 can also restore the wild type transcriptional activity of various p53 hot spot 
mutants remains to be established.  
 While there is overwhelming evidence that demonstrates that there is ID4 and p53 






we hypothesized that ID4 acts as tumor suppressor by regulating p53 expression and/or 
function. To investigate this hypothesis the following aims were proposed: 
1. Determine whether ID4 regulates p53 expression and/or stability. 








REVIEW OF LITERATURE 
 
2.1 Prostate and Prostate Cancer 
 The human prostate glands are paired, branched, secretory structures that bud 
from the urogenital sinus (UGS) in a testosterone-dependent process.  The prostate 
develops from UGS, which is part of the cloaca.  Urogenital sinus is a midline structure 
with epithelial layer surrounded by a mesodermally derived mesenchymal layer and is 
found at the neck of the developing bladder.46 The UGS is found in both male and female 
humans at about 7 weeks of gestation.47 Prostatic morphogenesis occurs once the UGS is 
distinguishable at 10-12 weeks. The adult human prostate has a compact morphology and 
is about the size of a walnut (Figure 3A).  The adult prostate is organized into three 
zones, a central zone, a transition zone, and a peripheral zone (Figure 3B). 48  The paired 
central zone is posterior to the stromal region. Interior to the central zone is the transition 
zones which is located on either side of the urethra. The transition zone represents the 
smallest zone in the normal prostate.49 The peripheral zone is the largest region of the 
normal adult prostate, which is located on the posterior side of the prostate. The 
significance of this architecture is based upon the relationship of these zones to prostatic 






among aging men, occurs mainly in the transition zone, whereas prostate carcinoma 









Figure 3. The adult prostate and surrounding structures. (A) The base of the prostate is located at the 
bladder neck. The urethra bisects the prostate. Image taken from http://www.cancer.gov/cancertopics/. (B) 
The three histologically distinct zones are shown: the central zone, the transitional zone, and the peripheral 
zone. Figure taken from Prostate Histology April 13, 2012 (2003-2012) Pathology Outlines.com, Inc. 
 
Mature prostatic ducts consist of three major cell types luminal secretory 
epithelial cells, basal epithelial cells and stromal smooth muscle cells.51 Differentiation 
markers can distinguish these cell types from one another. The expression markers for the 
luminal cells are androgen receptor and cytokeratins 8 and 18. Markers for basal 
epithelial cells are p63, cytokeratins 4 and 14.  There are also less common cell types that 
include neuroendocrine cells and rare basal epithelial cells that have unique marker 
expression profiles and are candidates for epithelial stem cells.51b The stromal layer is 
mostly composed of smooth muscle, but also contains fibroblasts, neuronal, lymphatic, 








vimentin.  Neuroendocrine cells are a minor population of cells in the normal prostate, 
are androgen-independent, and express chromogranin A, serotonin, and neuropeptides.46 
Prostate cancer (PCa) is the most prevalent solid tumor and a leading cause of 
cancer-related deaths among males in the United States, with an estimated 238,590 and 
233,000 new cases diagnosed in 2013 and 2014 respectively, and 29,720 deaths in 
2013.52 In 2015, it is estimated that 220,800 new cases will be diagnosed with 27,540 
estimated deaths according to the American Cancer Society. Due to technical 
improvement in screening and diagnostics, early surgical resection and introduction of 
novel anti-neoplasm agents, the incidence of PCa has been declining approximately 
2.4% annually from 2002 to 2011. The mortality of PCa has dropped 3.3% each year 
over the last decade, with elevated overall survival rate from 66% in the 1970s to 99.6% 
currently.52b, 53 
Most prostate cancers are adenocarcinomas, which arise from glandular epithelial 
cells. Prostate cancer rarely begins from the tissues surrounding the gland.54 Prostate 
intraepithelial neoplasia (PIN) is defined by “neoplastic growth of epithelial cells within 
pre-existing benign prostatic acini or ducts.”55 PIN is widely accepted as a precursor to 
prostate cancer.56 Prostate carcinoma is usually observed near the surface of the glands, 
which can be diagnosed during a digital rectal examination.57 As the tumors grow, the 
prostate expands around urethra and cause urinary problems with time it starts to invade 
surrounding organs such as seminal vesicle, neck of the bladder, lymph nodes and later 
prostate cancer can spread to bones, spine and pelvis. Metastasis often occurs in the 






American cancer society has identified five risk factors, which may increase the 
likelihood that a person develops prostate cancer: family history, age, race, nationality 
and diet.59 It has been found that African Americans have higher rates of prostate cancer 
incidence compared to that of Caucasians and Asian men.60 The risk of prostate cancer 
increases with age: one out of 6 American men during their life time is diagnosed with 
the disease.57 The therapeutic approaches such as radical prostatectomy and radiotherapy 
are considered curative for localized disease, yet no treatments for metastatic prostate 
cancer are available that significantly increases patient survival.61 Epidemiological 
studies have shown environmental factors such as diet is also a factor that increases the 
risk of prostate cancer. 
2.1.1 Androgens and Androgen Receptor (AR) 
 AR is a nuclear hormone receptor consisting of eight exons, which encode four 
functional domains: the NH2-terminal domain (NTD), DNA-binding domain (DBD), the 
hinge region and ligand-binding domain (LBD).62 The NTD accounts for majority of AR 
transcriptional activities, and the LBD binds androgens and transfers AR to the nucleus. 
The DBD, composed of two zinc fingers, is critical to DNA recognition and binding; 
whereas the hinge domain regulates the translocation of AR into the nucleus.63 PCa cells 
depend on androgens for growth and survival via the AR axis, and the roles of AR in 
maintenance of prostate tissue lineage, as well as in PCa initiation and development, are 
the basis for the effectiveness of androgen depletion therapy (ADT).63a, 64 Since Huggins 
and Hodges first demonstrated that PCa was hormone responsive and castration could be 






signaling have never been halted.65 Unfortunately, although surgical or chemical 
castration is highly effective in shrinking tumor burden decreasing serum PSA levels, and 
improving survival rate during initial treatment, PCa recurs after a median duration of 
response for 12 - 24 months and gradually develops into castration resistant prostate 
cancer (CRPC).53b  
Many studies have suggested that CRPC cells express mutated AR, which 
exhibited enhancement in both gene expression level and functional sensitivity. In 
clinical settings, AR amplification, promiscuity, and splice variant isoforms were more 
frequently observed in PCa previously treated with ADT, as compared to primary PCa 
without any treatment.62, 66 Therefore, it is generally believed that most CRPC cases are 
not truly hormone refractory, in which AR transcription is aberrantly reactivated despite 
low serum level of androgen after castration.62, 64 Conversely, mutations involving the 
AR gene were found in up to around 44% of CRPC cases.67 Moreover, hundreds of types 
of mutations in the AR have been identified, though 90% are non-sense and missense 
mutations.68 AR mutations mainly occur in the LBD and NTD, with only 7% mutations 
in the DBD and 2% in the hinge region. Mutations in the LBD, which were demonstrated 
to increase the sensitivity and decrease the specificity of the ligand binding, are clinically 
significant. 53b, 63a, 69 
2.1.2 Molecular Mechanisms of Prostate Cancer   
Since Huggins and Hodges’ initial discovery, research efforts to elucidate the 
molecular basis of prostate cancer has been at the forefront of cancer research.  A number 






have been developed that recapitulate several aspects of human prostate cancer initiation 
and progression. Most studies have centrally focused toward the role of androgen 
receptor (AR) in prostate cancer.74 As aforementioned AR, a member of the nuclear 
receptor superfamily, is required for normal prostate function and is involved in cyto-
differentiation of the prostate epithelial cells.75 In a majority of prostate cancer cases, AR 
function contributes to the survival and proliferation of cancer cells in primary disease 
and in most cases the presence of AR continues to be indispensable after progression to 
hormone independent disease.29, 76 However, the prostate epithelial specific AR knockout 
mouse 77 also develops prostate cancer, suggesting that AR function is not absolutely 
required for disease development.  Also, unlike other cancers (most notably breast and 
colorectal) where a familial mutation in a single gene leads to a higher risk of developing 
the respective cancers, no such major risk allele has been identified for prostate cancer to 
date. The heterogeneity of prostate cancer suggests that there could be multiple initiating 
events leading to inactivation of tumor suppressors and/or activation of tumor 
promoters/oncogenes that could at some point of disease progression cross-talk with 
AR.78 These early or late events may promote the transition of androgen receptor from a 
tumor suppressor to an oncogene.  
2.1.3 Genetic Disposition in Prostate Cancer Progression 
 Genetic disposition has been shown to play a pivotal role in prostate cancer 
progression since studies have shown a significant amount of prostate cancer cases are 
considered to be hereditary.79 Polymorphisms have been implicated in prostate cancer 






Polymorphisms are DNA sequence variation in genes that are associated with hormone 
response, DNA repair, cell protection, and nucleotide metabolism. Gene amplifications as 
a result of chromosomal alterations have been observed in many cancers.  The frequency 
of structural chromosomal alterations have been found to be increased in advanced stages 
of prostate cancer.  Specific chromosomal regions have been identified as having a role in 
chromosomal alterations, these regions include 5q, 6q and 7p.80   
The heterogeneity of prostate cancer has led to the investigation of inactivation 
of critical tumor suppressor genes such as p53, retinoblastoma (RB), and Phosphatase 
and tensin homolog (PTEN), which are the most notable tumor suppressors and are 
inactivated, silenced or mutated in cancers.81 82 Chromosomal alterations and point 
mutations are responsible for functional inactivation of p53 in prostate cancer. 83 Point 
mutations have also been reported for PTEN that result in transcriptional reduction of 
expression.82 The Rb gene is located at 13q14, which is a chromosomal region 
frequently deleted in prostate carcinoma suggesting that tissue specific tumor suppressor 
genes play key roles in prostate carcinoma.84  
2.2 Tumor Suppressor p53 “Guardian of the Genome” 
The tumor suppressor protein p53 remains one of the most intensively studied 
genes in cancer biology and therapy.85 It was regarded as an oncogene for 10 years after 
it was discovered more than twenty years ago.86 Subsequent studies revealed that p53 
(encoded by the human gene TP53), in fact was a tumor suppressor, which binds to a 
specific DNA sequence and transactivates target genes leading to cell cycle arrest and/or 






transcription factor, which regulates a large number of genes in response to a variety of 
cellular insults, including oncogene activation and DNA damage.87 These signals activate 
p53 primarily through post-translational modifications that result in augmented p53 
protein level and transactivation activity.87  
2.2.1 p53 and Cell Cycle 
p53 plays a role in the regulation of the cell cycle, by inducing a cell cycle arrest. Cell 
cycle arrest allows the cell time to repair DNA damage before entering the critical stages 
of DNA synthesis and mitosis.  p53 can use nucleotide excision repair and base excision 
repair mechanisms before the arrested cells are released back into the proliferating pool.88 
One of the most well-known and studied p53 target genes is cyclin dependent kinase 
inhibitor, p21. p21 is a known cell cycle regulator, which is a primary mediator of p53-
dependent G1 cell cycle arrest following DNA damage. p21 is upregulated by p53 in 
response to stress and DNA damage,89 therefore blocks cyclin E/CDK-mediated 
phosphorylation of Rb and release of E2F, which functions to induces the expression of 
gene involved in S phase entry.90 Increased expression of GADD45 results in p53-driven 
G2 cell cycle arrest.91 This occurs through the binding of GADD45 to CDC2, which 
prevents cyclin B/CDC2 complex formation and inhibits kinase activity.91a  
2.2.2 p53 and Apoptosis 
  One of the tumor suppressive functions of p53 is to monitor cellular stress and to 
induce apoptosis as necessary. In situations of cell stress and damage p53 can initiate 
apoptosis and eliminate damaged cells.92 Apoptotic genes that regulate apoptosis includes 






Scotin, p53AIP1, and many others.  The p53 apoptotic targets are divided into two 
groups, extrinsic pathway (Fas/CD95, DR5/KILLER, DR4) and intrinsic pathway (Bcl-2 
family pro-apoptotic and anti-apoptotic members).93  
 When the extrinsic pathway (also referred to as death receptor pathway) is 
activated, p53 initiates apoptosis through activation of the death receptors located on the 
plasma membrane.94 p53 signals the inhibition of the production of IAPs (inhibitor of 
apoptosis proteins), which controls apoptosis.94 Alternatively, the intrinsic pathway is the 
main pathway activated in p53 dependent apoptosis, whereas extrinsic pathway is used to 
supplement the apoptotic response.95 The intrinsic pathway is the mitochondrial pathway, 
and is activated when cells undergo stress. This pathway is regulated by the Bcl-2 family 
proteins.96 Bcl-family consists of both pro-apoptotic members (BAX, BAK, BCL-xl, 
BH3-only members Bid, Bad, Puma, and NOXA) and anti-apoptotic members (BCL-2 
and BCL-Xl). When the intrinsic pathway is activated, the pro-apoptotic proteins such 
BAX, BID, PUMA, NOXA, and p53aIP1 localize to the mitochondria which causes loss 
of the mitochondrial membrane potential and cytochrome c release. Next the grouping of 
the apoptosome complex with Apaf-1 triggers the activation of caspases through caspase 
9, which executes apoptosis.97 Loss of Bax is responsible for nearly 50% of accelerated 
tumor growth in brain tumors.98  BAX is also required for p53-dependent apoptosis in 
colorectal cancer cells, but is dispensable in apoptosis of thymocytes and intestinal 
epithelial cells.93  In some instances cell cycle arrest can protect cells from apoptosis.  






cycle arrest or apoptosis in colorectal cancer cells, if p21 is disrupted cells die through 










Figure 4. p53 pathway, depicting p53 regulatory network.  P53 can be regulated by MDM2 and 
p14ARF.  p53 can also regulate p21, MDM2, BAX, and Gadd45, which eventually leads to cell-
cycle arrest and apoptosis.  This figure was taken from. 100 
 
2.2.3 Acetylation of p53 
Acetylation has many important effects on p53. It increases p53 protein stability, 
binding to low affinity promoters, association with other proteins, antiviral activities, and 
is required for its checkpoint responses to DNA damage and activated oncogenes.101 Six 
acetyltransferases have been identified that modify p53 at lysines predominantly in the C-
terminus or its central DNA binding domain. Acetylation of p53 directly affects its 
transcriptional activity by opening up its normally closed conformation or by altering its 
binding to certain response elements in gene targets (Figure 5). In general, these 
modifications are mediated by two different groupings of acetyltransferases, 






sites of p53 acetylation since loss of one or more sites, including all seven C-terminal 
lysines in mouse p53, can be largely compensated for by acetylation of remaining 
lysines.102 However, combined loss of eight major acetylation sites in human p53 (8KR 
mutant altered at K120, 164, 370, 372, 373, 381, 382 and 386) renders p53 
transcriptionally inert and prevents its induction of cell cycle arrest and/or apoptosis.101b 
Conversely, in many cell types the inhibition of histone deacetylases (HDACs) that 
remove acetyl groups from p53 (i.e., HDAC1 and SIRT1) causes increased p53 
acetylation and p53-dependent activation of apoptosis and senescence.103 Together, these 
findings suggested that acetylation is an essential regulator of the anti-cancer functions of 
p53. 
 
                      
Figure 5. The acetylation of p53 stimulates its sequence-specific DNA-binding activity. Acetylation of 
lysine residues in C-terminal region results in neutralization of positive charges and leads to the disruption 
of interactions between the C-terminal domain and the core domain. DNA-binding domain adopts an active 









2.3 p53 and Cancer 
2.3.1 p53 Mutations  
p53 function has been found to be compromised in tumor cells, usually as a result 
of somatic mutations, which occur in approximately half of all human cancers and 
constitute a cornerstone in tumorigenesis. In principle, emergence of a p53 mutation 
within a cell might have three, not mutually exclusive, types of outcomes.1 First, such 
mutation is expected to abrogate the tumor suppressor function of the affected TP53 
allele, reducing the overall capacity of the cell to mount a proper p53 response; if both 
alleles eventually become mutated, or if the remaining allele is lost, such cells will be 
totally deprived of anticancer protection by p53.2 Second, many common mutant p53 
isoforms can exert dominant–negative effects over coexpressed wild type 53, largely by 
forming mixed tetramers that are incapable of DNA binding and transactivation. Hence, 
even if one wild-type allele is retained, the cell may be rendered practically devoid of 
wild type p53 function through such mechanism, particularly if the mutant protein is 
expressed in excess over its wild type counterpart.3 Third, and most relevant, the 
emergent mutant p53 protein possess activities of its own, often not present in the 
original wild type p53 protein, which can actively contribute to various aspects of tumor 









2.3.2 Gain-of-Function Mutant p53 
The concept of mutp53 GOF was formally introduced in the early 1990s, when it 
was shown that mutp53 isoforms of both human and mouse origin, but not wild type p53, 
could transform p53-null cells and give them the ability to form colonies in soft agar in 
vitro and tumors in mice.104 Moreover, the most convincing support for the gain-of-
function hypothesis came from mice engineered to harbor some of the most frequently 
occurring tumor-associated p53 mutations. In comparison to heterozygous or null 
(p53+/– or p53–/–) mice, animals with one mutant allele show a different and broader 
tumor spectrum — with the appearance of more carcinomas and sarcomas, in addition to 
lymphomas. Interestingly, these mutant p53 driven cancers play a pivotal role in tumor 
progression and also aided in genomic instability.2-3, 14 A whole host of oncogenic 
functions of mutant p53 has been characterized in cell culture models, including: an 
ability to promote invasion, migration, angiogenesis, stem cell expansion, survival, 
proliferation and tissue remodeling.4 These evidences has aided in the theory the mutant 
p53 has a wide range of response and acts in several different pathways to effect tumor 
progression. 
2.4 Mechanisms of Mutant p53 Function 
There is much discussion of the molecular mechanism by which mutant p53 may 
function, notably there have been numerous characterizations of pathways mutant p53 
may employ. These molecular mechanisms as laid out by Muller et al., 2013, consist of 






p53 with other proteins, including other transcription factors, or proteins not directly 
related to the regulation of gene expression.4  
2.4.1 Mutant p53 Binds to DNA to Alter Gene Expression 
Although, two thirds of missense mutations in the DBD, including all hotspot 
mutants, abrogate the ability of p53 to activate target genes, modulation of gene 
transcription by mutant p53 is well documented as an important gain-of-function 
mechanism.105 Tumor derived mutant p53 proteins have often be seen to retain the N-
terminal transcriptional transactivation domains and most mutant p53 function has been 
attributed to direct or indirect abilities to regulate gene expression.106 Most amino acid 
substitutions occur within the DNA-binding domain of the majority of tumor-derived p53 
mutations may change, rather than completely abolish, sequence-specific DNA binding. 
Mutant p53 has been shown to have DNA binding ability, though most cases show that in 
mutant form, p53 is unable to bind its wild-type response element. Mutant p53 has been 
shown to bind to other parts of DNA such as the nuclear matrix, providing an alternate 
mechanism to regulate gene expression.4  
2.4.2 Mutant p53 Binds to Transcription Factors  
Another well established mechanism for gene specific transcriptional regulation is 
the interaction of mutant p53 with sequence-specific transcription factors, which result in 
either augmentation or attenuation of their activity.  Besides p63 and p73, which are well 
characterized transcription factors that interact with mutant p53. SP1 and ETS1 also 
interact with wild-type p53.107 Interestingly, the effects of mutant and wild-type p53 are 






and wild-type p53.108 The best-described transcriptional functions of mutant p53 relate to 
its ability to interact with other transcription factors and modulate the expression of their 
target genes 109. In some cases, mutant p53 increases the activity of the transcription 
factor partner, with further complexity added by the role of cellular stimuli, tran-
scriptional cofactors and other proteins.  
2.4.3 Mutant p53 Interacts with Proteins to Change their Function 
The interaction of mutant p53 with transcription factors can also be inhibitory. 
Probably the best understood of these involve these interactions.110 For example, studies 
have previously shown that the anti-proliferative effect of TGF-b is facilitated by the 
presence of wtp53, elucidating that these two pivotal signaling pathways are necessary in 
suppression of early stages of tumor progression.111 Moreover, current investigation of 
cross-talk and mutant p53 have shown a fascinating correlation as well. Intriguingly, 
mutant p53 can repress the expression of TGF-b receptor type II, thus attenuating TGF-b-
mediated signaling. Also, in response to TGF-β treatment, SMAD2 promotes the 
complex between mutant p53 and p63 112, leading to the inhibition of p63-driven gene 
expression.  
Although there has been much focus on the role of mutant p53 in affecting 
transcriptional programs, mutant p53 also binds and modulates the function of proteins 
that are not directly involved in transcription. For example, by interacting with MRE11, a 
DNA nuclease required for DNA repair, mutant p53 prevents the MRE11–RAD50–NSB1 
complex from phosphorylating ATM, leading to impaired homologous recombination.3, 






binding is topoisomerase 1 (Top1), which maintains topology of DNA. Whereas wild-
type p53 both promotes and counteracts Top1 function, mutant p53 has specifically lost 
the negative regulation of Top1, resulting in hyper-recombination and genomic 
instability.114  
A major hallmark of cancer progression is a gradual increase in genome 
instability, manifested all the way from higher mutation rates to gross aberrations in 
chromosome number and structure. A link between mutant p53 and increased genomic 
instability was clearly demonstrated by showing that human mutant p53 can disrupt 
normal spindle checkpoint control, leading to accumulation of cells with polyploidy 
genomes.115 
2.4.4 Stability of Mutant p53 
A major phenomenon of mutant p53’s ability to endow the cellular environment 
with a whole host of new abilities lies within its increased stability as compared to its 
wild type counterpart, which is quickly degraded. So, how does mutant p53 gain its 
newfound stability? The degradation of wild-type p53 is achieved through a multitude of 
mechanisms, involving several E3 ubiquitin ligases that target p53 for ubitiqunation and 
subsequent proteasomal degradation.116 Of those, the best studied and probably the most 
important driver of p53 degradation is MDM2, an E3 ligase and also plays a role in 
repressing p53 mRNA translation. Escape from MDM2-mediated degradation is therefore 
an appealing mechanism for mutant p53 stabilization,117 however; mutant p53 is still 
susceptible to MDM2-mediated degradation.117b, 118 






cancer-associated mutp53 isoforms lack the ability to transactivate wild type p53 target 
genes. The MDM2 gene is a classical positive transcriptional target of wild type p53, and 
this drives a negative feedback loop that helps maintain wild type p53 levels very low in 
unstressed cells. However, mutant p53 fails to transactivate the MDM2 gene. Hence, 
MDM2 protein levels are likely to be rather low in cells that express only mutant p53.117a 
2.4.5 Animal Models for Mutant p53 GOF  
Increasingly animal models are playing a larger role in demonstrating mutant p53 
GOF capabilities and giving insight to the biological significance of these newfound 
abilities. Several studies have also shown that several mutants often found in various 
cancers known, often referred to as hotspot mutants were also shown to enhance tumor 
formation in p53-null fibroblasts and also in human p53-null osteosarcoma cells 104, 119, 
establishing that mutant p53 indeed has GOF.  
2.4.6 Mutant p53: Different in the Same Way? 
Similarly, most studies indicate that cancer-associated mutant p53 has gain-of-
function activities that aid the invasiveness and metastatic properties of the cell. The 
gain-of-function activities of mutant p53 in cancer models, poses the question are all p53 
mutations created equal and why are there so many? For example, Gurova et al.120 tested 
this paradigm when they used p53 mutants found in prostate cancer cell line, DU145 that 
has two different p53 mutations P223L and V274F. They used a p53-null cell line (PC3) 
to study both mutants individually and when coexpressed. Gurova et al.120 found that 
these mutants are different from wild-type p53 protein in at least some of their properties. 






denatured conformation of the DNA-binding domain, lacks transactivation ability) than 
the p53–223Leu one (wild- type conformation, transactivation ability), they both showed 
some properties that are unusual for tumor-derived mutants, and they more closely 
resemble wild-type p53 (can be stabilized by DNA damage, cause growth suppression in 
some cell types, do not possess dominant-negative activity). However, these relatively 
“weak” mutants create p53 protein with new structural and functional properties when 
coexpressed in one cell. Whereas when both mutants were coexpressed they were seen to 
serve a similar function as in DU145 cells.120 
Interestingly, studies have shown that the p53 mutations are indeed not all func-
tionally equivalent.4 It is widely been reported that mutations in the DNA-contacting 
residues of p53 have a less dramatic effect on the folding of the p53 protein than the 
structural mutants.14 The native and denatured forms of p53 can be differentiated using 
conformation-specific antibodies, suggesting that the structural switch could reveal or 
obscure epitopes for binding to different partner proteins.5 On the other hand, mutant p53 
can engage in protein–protein interactions with a growing number of transcription 
factors, often being recruited to binding sites of those factors on chromatin, and modulate 
their transcriptional output both positively and negatively.15 Interaction studies of mutant 
p53 with p63 or p73 107-108, 121 have shown that the structural mutants bind p63 or p73 
with a much higher affinity than the contact mutants, although both groups of mutations 
have the ability of inhibiting p63 and/or p73 to promote invasion and metastasis or to 









2.5 Therapeutic Applications of p53  
Since p53 mutation, as well as wild-type p53 impairment is widely observed in 
human cancers, restoration of p53 function in tumors has been pursed as a promising 
strategy for cancer therapy.123 Also, it is also important to know whether tumors with 
different types of p53 mutations require other therapeutic approaches. The presence of a 
mutant form of the tumor suppressor gene p53 has the potential to disrupt the apoptosis 
pathway and cell cycle arrest after DNA damage, which results in increased radiation 
resistance and cell survival.4 Promising studies using wild-type p53 adenoviral or 
retroviral gene transfer in tumors are ongoing. Overexpression of p53 has been shown to 
be sufficient to induce apoptosis or sensitize the tumor cells to radiotherapy or 
chemotherapy in most cancer cells with reduced efficacy in tumor cells containing wild-
type p53.124 However, because gain-of-function mutants exert additional oncogenic 
functions, wild-type p53 gene transfer might not work in these tumors, and the malignant 
phenotype may be maintained. p53 antisense therapy 125 that blocks the function of the 
p53 mutant might be more useful for tumors with gain-of function mutants. Other 
promising therapies that might interfere with the different properties of the gain-of-
function mutants are structure-based rescue therapies.126 Since, mutant p53 proteins are 
highly expressed in many cancers, making them extremely attractive targets for therapy. 
Current strategies have focused on destabilization or inactivation of mutant p53, or 






to achieve, but has gained great traction recently with current research using mouse 
models showing that the activation of wild-type p53 is established tumors can lead to 
efficient tumor regression.4  
2.6 ID4-p53 Cross-talk 
 The molecular mechanism by which mutant p53 may function have been 
reviewed extensively.4 These pathways include alterations in the DNA-binding ability of 
mutant p53, interaction of mutant p53 with other proteins, including transcription factors 
or proteins not directly related to the regulation of gene expression. It is clear that the 
effects of mutant p53 are strongly context dependent, and interactions that promote 
activity in some circumstances may be inhibitory in others. 
Fontemaggi and colleagues have extensively characterized the molecular 
interaction between ID4 and mutant p53 in promoting neo-angiogenesis in breast cancer 
127. In breast cancer cell lines ID4 is a transcriptional target of gain-of-function p53 
mutants R175H and R280K in SKBr3 and MDA-MB-231 but not in MCF7 breast cancer 
cells expressing wild type p53. The protein complex involving mutant p53–E2F1-p65 
assembles on specific regions of the ID4 promoter and positively controls ID4 expression 
127. The study further demonstrated that mutant p53 R273H had the highest regulatory 
control over ID4 expression.127 Overexpression of ID4 in SKBr3 cells, stabilized the 
mRNA of pro-angiogenic factors IL8 and GRO- which resulted in the increased 
secretion of the respective proteins.  ID4 expression was also increased in response to 






involving the knockdown of mutant p53 abrogated this response, indicating that in 
response to DNA damage mutant p53 in complex with E2F1 and p300 bind to the CDE 
element closest to the transcriptional start site, on the ID4 promoter, to achieve “mutant 
p53 associated” chemo-resistance.128 Thus, direct interaction between mutant p53 and 
E2F1 on the ID4 promoter supports the oncogenic functions of mutant p53 in at least 
breast cancer. 
ID4 functions as a tumor suppressor in ER+ve breast tumors where it is frequently 
inactivated by promoter hypermethylation; however, ID4 displays oncogenic activity in 
ER-ve breast cancer cells SKBr3 and MDA-MB-237 that express mutant p53.128 These 
results suggest that ER may have a role in regulating ID4 dependent expression of mutant 
p53. The corresponding estrogen receptor levels in the meta-analyses discussed above 
were not reported but could determine the outcome of the ID4-mutant p53 cross-talk. 
These conflicting results between cell lines and clinical studies suggest that the ID4 
regulatory mechanism could be controlled by a complex mechanism that still remains to 
be investigated.  
2.7 Molecular Dynamic Studies of p53 
More than 80% of missense mutations in p53 found in human cancers are located 
in the core DNA domain.129 Many of these mutations disrupt DNA binding directly or 
reduce the folding or stability of the core domain suggesting that DNA binding is critical 
to p53 function. Damaged cells harboring p53 mutants that abrogate wild-type p53 
functionality will begin and continue uncontrolled cellular division and often equip the 






cell.4 The concept of mutant p53 gain of function was formally introduced in the early 
1990s, when it was shown that mutant p53 isoforms of both human and mouse origin, but 
not wild-type p53, could transform p53-null cells and give them the ability to form 
colonies in soft agar in vitro and tumors in mice.104 Moreover, the most convincing 
support for the gain-of-function hypothesis came from mice engineered to harbor some of 
the most frequently occurring tumor-associated p53 mutations.4  
The structure of the p53 core domain, commonly associated p53 mutations and 
their complex with DNA are currently under intense investigation.5,130 However, studies 
of the core domain of wild-type p53 have revealed the details of protein folding, DNA 
recognition, and given some insight into potential mechanisms of some cancer-associated 
mutations. Some of these missense mutations are temperature sensitive e.g. the P223L 
and V274F in DU145 prostate cancer cells that retain transactivation functions at lower 
temperatures (32C), 131 while other mutations result in complete loss of activity (gain of 
function/ loss of transactivation).  Extensive structural studies suggest that the 
temperature sensitive mutants and/or other mutants promote near wild type structure of 
p53 under certain conditions.  Protein-protein interaction between wild type and mutant 
p53 core domains in higher-order p53 complexes has also been a subject of experimental 
and modeling studies.5, 132 Based on these results, we hypothesized that theoretical 
modeling of p53 and its mutants could provide a parameter that can link the type of 
mutation with p53 structure and possibly function. These structural simulation parameters 
of various known p53 mutations could be used to establish an association between cancer 






structure of mutant p53 to simulate as a wild type protein.  Studies have suggested that 
common p53 cancer mutants exhibit a variety of distinct local structural changes while 
the overall structural scaffold remains largely preserved.130 Thus, a focus on the structural 
changes associated with the local core DNA binding domain may be more informative in 
terms associating the severity of mutants with function. 
Modeling studies via computational methods, including molecular docking, 
molecular dynamics (MD) simulation and binding free energy prediction are usually 
applied to supplement the experimental studies in order to understand the mechanism at 
an atomic level or to improve the efficiency of molecular design or discovery.133 Studies 
including theoretical modeling of p53, and the p53 conformation changes induced by 
protein-protein and protein-ligand interactions, including peptide and small molecular 
inhibitors have significantly expanded our current understanding of the dynamic nature of 
p53 structure.133-134 While there have been several studies discussing the dynamic 
simulations of p53 in recent years, the dynamics and flexibility of mutation induced 
conformational changes of p53 have not been completely characterized or understood. 
Additionally, the dynamics characteristic of other domains of p53 has not been fully 
studied. In this study, we aim to understand via computational analysis of p53 structural 
models the energy differences of wild-type and mutant forms of p53. Moreover, this 
study will aid in providing better understanding of how disparate energy, temperature 
sensitivity, and missense mutations differences amongst different forms of mutant p53 






The molecular dynamics study presented herein was inspired by many experimental 
observations that focused on the restoration of mutant p53 due to the intrinsic flexibility 
of its domain structure.7b Studies have shown that certain p53 mutants can be rescued via 
temperature (temperature sensitive mutants P223L and V274F), and artificial means such 
as small molecules and short peptides (reviewed in 135). Aforementioned studies in our 
laboratory revealed that mutant p53 could be restored to function as wild-type via 
physiological means through acetylation of lysine residues (K373).43 Thermodynamic 
studies revealed that the R248Q mutant is stable at sub-physiological low 
temperatures.136 The R248Q stability was less than that of the wild-type protein by ∼2 
kcal/mol. The mutant structure also retained a two-stage unfolding transition, similar to 
the wild-type protein 137, which indicated well-defined structures at low temperature. 
PRIMA-1 (p53-reactivation and induction of massive apoptosis-1, APR-017, 2,2-
bis(hydroxymethyl)-1-azabicyclo [2,2,2]octan -3-one)138 and its methylated form, 
RRIMA-1MET (APR-246)139 was shown to restore sequence-specific DNA binding region 
of R273H and R175H by forming adducts with thiols in mutant p53 and activating 
several p53 target genes and promoting apoptosis in human cancer cells.12 Thus, 
thermodynamic stability calculated exclusively through global energy minimization 
simulations could provide an insight into the structural flexibility of mutant p53.  Our 
long-term goal is to use these simulations to discover mutants that could be 1) sensitive to 
restoration of mutant p53 biological activity and 2) severity of the mutant that can 








In conclusion, p53 is characterized as a tumor suppressor due to its role in 
apoptosis, cell cycle arrest, DNA damage, senescence, differentiation, and DNA repair.  
P53 is at the heart of many stress response pathways and regulator of many genes that 
modulate various cellular processes such as DNA damage control, cell cycle arrest, 
senescence, and apoptosis.  Mutations of p53 can provide an environment for genetic 
instability of tumor cells, which can result in accelerating tumor progression.  
2.9 ID4 Function, Sequence and Structural Properties 
The origins of ID proteins can be traced back to the D. melanogaster extramacrochaetae 
(emc) gene (reviewed in 21b).  As orthologs of emc, the four ID proteins are paralogs that 
appeared through gene duplication in vertebrates.   
ID4 only shares the core HLH domain but divergent N- and C- terminal 
domains18a compared with other ID proteins (Figure 6). Therefore, ID4 can be considered 
as a remote homologue of ID1, 2 and 3. ID4 is also the longest protein within the ID 
family with 161 residues (Figure 6). The sequence divergence of ID4 at the N-terminal 
(Alanine rich) and C-terminal (Proline rich) (Figure 6) could allow distinct ID4 functions 
as opposed to the other ID protein family members.   
            
Figure 6. The red lines indicate the alanine and proline rich regions at the N- and C-terminal of ID4. The 








The poly-alanine rich N-terminal tract in ID4 appears to be rapidly evolving.  
Similar to the poly-alanine tracts of HOXA13140 and class III POU141 transcription factors 
that appeared only in mammals, the poly-alanine tract in ID4 also first appeared in 
primitive mammals such as opossum (marsupials) but is absent in lower vertebrates such 
as alligators, xenopus, zebra fish and birds (Gallus, Finch). Thus, the poly-alanine tract in 
ID4 appeared independently in paralogs, hence conserved for functional reasons. The 
poly-alanine tract in ID4 is consistent with similar tracts which are preferentially found in 
many transcription factors and lies outside, usually towards the N-terminal of the 
functional domains (such as N-terminal to HLH domain in ID4).  This tract generally acts 
as a flexible spacer element located between the functional domain of a protein and 
therefore essential to protein conformation, protein–protein interactions and/or DNA 
binding 142. The length of the poly-alanine tract in ID4 (n=10) is also within threshold for 
normal function whereas an increase in the length beyond this threshold results in human 
diseases (<10).143 In fact, structural studies suggest that none of the N- and C- terminal 
fragments of  any of the ID proteins adopts a helical formation, except the N-terminal 27-
64 fragment of ID4 21a, a motif that is dictated by the Alanine residues 39 and 48 (Figure 
5).  Thus the alanine rich N-terminal domain could be a functionally important domain in 
ID4. In this context, the unique function of ID4 suggests the potential for positive 







The over-representation of proline within the C-terminal end may also impart 
additional structural and functional features unique to ID4. Proline is a strong promoter of 
intrinsic disorder144 and thus likely supports the internal disorder at the ID4 C-terminal 
domain. Indeed, the overall percent disorder in ID4 is highest among all the ID proteins: 
ID4-70.2%, ID2-59.7%, ID3-35.29% and ID1-28.6%. The low complexity proline rich 
region in ID4 suggest that ID4 like other internally disordered proteins also lacks a 
defined 3-D structure at the C-terminal that favors protein-protein interactions by 
presenting a larger interaction surface allowing multiple binding partners.145 Thus, 
structural divergence through acquisition of new functionally relevant domains in ID4 
suggests a potential novel role in development and differentiation as compared to IDs 1, 2 
and 3. 
2.10 The Role of ID4 During Development and Differentiation 
ID proteins are expressed by essentially all cell lineages at some point during 
embryonic development. Consensus suggests that ID expression is highest in 
undifferentiated, proliferating populations that is subsequently down-regulated as 
primitive cells exit from cell cycle and terminally differentiate.19c 
By in situ hybridization on mouse development post-gastrulation, ID1, 2 and 3 
expression is observed in multiple tissues whereas the expression of ID4 is non-
overlapping and restricted to neuronal tissues and in the ventral portion of the epithelium 
in developing stomach.146 In adult human tissues, ID4 expression is observed in brain, 







ID4 is highly expressed in osteoblast149, adipocytes150, prostate epithelial cells27 
neurons151, testicular Sertoli cells152 and during differentiation in glial cells153 supporting 
its role as a pro-differentiation factor.  ID4 is also expressed in germ cells at various 
stages of development: spermatogonial stem cells154, spermatocytes, pachytene 
spermatocytes and spermatids.155 ID4 is also required to maintain spermatogonial stem 
cell renewal.154   
Unexpectedly, overexpression of ID4 in oligodendrocyte progenitors cells (OPC) 
prevents differentiation, associated with a decrease in the endogenous expression of all 
myelin genes. Conversely, OPCs lacking ID4 display precocious differentiation and 
increased apoptosis156 suggesting that ID4 is required for the development of 
oligodendrocytes. A progressive decline in ID4 transcription is also a part of the 
intracellular timer that helps determine when oligodendrocyte precursor cells withdraw 
from the cell cycle and differentiate.157 This unique phenotype supports the role of ID4 as 
inhibitor of differentiation, the classical function of ID proteins. 
Immuno-cytochemical studies have shown that ID4 is localized to the nucleus in 
OPCs 157 and spermatids, but remains cytoplasmic in spermatocytes.155   
Collectively, the studies suggest that ID4 can act as pro- or anti-differentiation 
factor in a cell specific manner. The integration of various cellular events such as 
response to specific ligands and possibly cell specific interacting proteins could 







2.11 ID4 Knockout Mouse Models 
2.11.1 Global ID4 Knockout Model  
Two different global ID4 knockout (ID4-/-) mouse models exist. In the first ID4-
/- model (strain 129X1/Svj,) developed by Mark Israel’s group (ID4tm1Mais in MGI 
database), exons 1 and 2 were replaced by GFP and neomycin-resistance genes via 
homologous recombination in JM-1 ES line.151 The second ID4-/- model (strain 
129P2/OlaHsd) was developed by Fred Sablitzky’s group (ID4tm1Fsky in MGI database).158 
In this model the sequence encoding HLH domain and most of the C-terminus of the 
gene was replaced lacZ-neo cassette. The cassette was inserted in-frame, allowing the 
expression of a fusion gene encoding the N-terminal 65 amino acids of ID4 fused to beta-
galactosidase.  
Both the ID4-/- mouse models displayed essentially similar phenotypes in the 
brain (decreased brain size, abnormal fat cell morphology) and mammary gland.  The 
ID4tm1Fsky model appears to have a more severe phenotype as a result of associated 
embryonic lethality (50% die in uteri or neonatally).  The surviving homozygous mutant 
mice lose weight rapidly probably due to a defect in abnormal adipose tissue 
development and osteoporosis with only 20% surviving through adulthood. A similar 
phenotype in the ID4tm1Mais model was not reported. 
2.11.2 ID4 and Neuronal Development  
During development, depletion of ID4 in mice also revealed its essential role in 
normal brain development and function where it is required for: neural stem cell 






developing cortex and hippocampus and proliferation in the ventricular zones.151, 158 In 
the absence of ID4, neural precursor cells proliferate more slowly than their wild type 
counterpart highlighting the essential regulatory role of ID4 during neural stem cell 
proliferation and fate determination. Though not investigated, but the cognitive abilities 
of ID4-/- mice could provide some interesting clinical correlates. 
2.11.3 ID4 and Mammary Gland Morphogenesis  
In mouse mammary gland, ID4 is expressed in cap cells, basal cells and in a 
subset of luminal epithelial cells where it promotes ductal elongation and branching 
morphogenesis.148 Targeted ID4 deletion impairs ductal expansion and branching 
morphogenesis as well as cell proliferation induced by estrogen and/or progesterone. ID4 
also maintained the survival of normal mammary cells as well as cultured mammary 
tumor cells. These normal and tumorigenic functions of ID4 were primarily achieved by 
suppressing p38MAPK activity.148 
2.11.4 ID4 and Spermatogenesis  
In mice lacking ID4 expression, quantitatively normal spermatogenesis was found 
to be impaired due to progressive loss of the undifferentiated spermatogonial population 
during adulthood.  ID4 expression was observed in spermatogonial stem cells (SSCs) in 
the mouse germline where it was shown to regulate self-renewal. Specifically, ID4 is 
expressed by a sub-population of type A single spermatogonia in mouse male germ 
line.154 GDNF, a key growth factor driving self-renewal ID4 expression was found to up-







2.11.5 ID4 and Osteoporosis  
A drastic reduction in osteoblast differentiation with a corresponding increase in 
differentiation toward adipocytes was observed in ID4-/- mice. ID4 promotes osteoblast 
differentiation by releasing Hes1 from Hes1-Hey2 complexes. Subsequently, Hes1 
increases the stability and transcriptional activity of Runx2, a key molecule of osteoblast 
differentiation, which results in an enhanced osteoblast-specific gene expression.149 
2.11.6 ID4 and Prostate  
A large cohort of studies demonstrating a strong association between loss of ID4 
expression in many cancers suggest that ID4-/- mouse could present with multiple 
cancers at some point in the lifetime.  Till date, the cancer phenotype has been well 
established only in the prostate of ID4-/- mice.  ID4 is highly expressed in wild type 
mouse prostate as well as normal human prostate. We have shown that ID4 is a key 
regulator in the normal development of various androgen receptor organs of the male 
genital tract in general and specifically of the prostate. Prostate from ID4-/- mice have 
smaller size, decreased branching morphogenesis and decreased differentiated luminal 
cells as determined by almost complete loss of NKX3.1 expression, a marker of 
differentiated luminal epithelial cells.27 A similar defect in branching morphogenesis in 
the developing mammary gland of ID4-/-148 therefore appears to be a consistent 
mechanism. The presence of PIN lesions, the earliest stage of prostate cancer27 in 6 
weeks old ID4-/- mouse prostate suggested that loss of ID4 may be an initiating event in 
prostate cancer development.  ID4 had no effect on androgen receptor expression as well 






genes such as the homeobox NKX3.1 decreased, that was in part due loss of AR binding 
to its respective response element.  In contrast, the expression of other AR target genes 
such as probasin and Myc increased suggesting that ID4 may differentially regulate AR 
binding to its corresponding binding site.  Furthermore, the expression Pten a known 
tumor suppressor is also decreased in ID4-/- mice.27 
Clearly, tissue specific ID4 knockouts need to be developed in order to fully 
understand its role in development, differentiation and disease. The existing global ID4 
knockouts should also be thoroughly analyzed since some of the effects could be subtle 
and may not result in easily identifiable large scale developmental phenotypes such as 
those observed in brain and reproductive tracts. 
2.12 ID4 and Cancer 
ID4 appears to act primarily as a tumor suppressor in most cancers as opposed to 
ID1, ID2 and ID3, which in most cases acts as tumor-promoters or supporting 
oncogenes.17 In a small subset of cancers, ID4 also acts as a tumor promoter (Figure 1).  
Beyond correlative studies showing ID4 expression in tumors, the underlying molecular 
mechanism remains largely unexplored.    
2.12.1 ID4 as a Tumor Promoter 
The role of ID4 as a tumor promoter is based on the evidence (experimental and 









2.12.2 Breast Cancer 
A clear picture relating ID4 expression with breast cancer has not emerged.  
Epigenetic silencing of ID4 is observed in Columnar Cell lesions (CCL) and Ductal 
Carcinoma In situ (DCIS)/invasive carcinoma159 and majority of sporadic breast 
cancers.160 ID4 expression is also absent in ER positive atypical ductal hyperplasia, 
ductal carcinoma in situ and invasive carcinomas but present in normal ER negative 
mammary epithelial cells161 suggesting that ER could negatively regulate ID4.160-161 
Increased ID4 expression is observed in basal cell-like breast cancer,162 triple negative 
breast cancer (TNBC) (including 4T1 mouse mammary cancer cell line163) but not in 
non-TNBC. Functional studies demonstrated that ID4 down-regulates BRCA1162, 164 and 
allows for anchorage-independent growth of breast (SKBr3) and ovarian (PA-1) cancer 
cells164b which are ER-ve. However, another study demonstrated that BRCA1 up-
regulates ID4 that correlates with increased BRCA1 and ID4 expression in normal breast 
and ovarian tissues.165 In meta-analysis, no significant association was found between 
ID4 and breast cancer.166  
The ID4 gene expression profile in The Cancer Genome Atlas (TCGA) dataset is 
consistent with results discussed above. ID4 is highly expressed in the normal breast 
tissue and in Basal cell like cancers (ER-ve).  Interestingly, ID4 expression was found to 








Figure 7. ID4 expression profile from The Cancer Genome Atlas database. The respective cancers (A; 
breast cancer, B: GBMand C: prostate cancer), the gene expression analysis platform and number of 
samples (N) used for analysis are indicated above each panel. The cluster is represented by decreased 
(green), increased (red) or no change (black) in ID4 expression. The bars toward the right of each cluster 
represent sample type and sub-type. The PAM50 array represents major molecular subtypes in breast 
cancer. The estrogen receptor status (ER) is indicated by + (present) and (−) absent. ANP: adjacent normal 
prostate, PCa: prostate cancer. 
 
2.12.3 Other Cancers  
ID4 expression is observed in Ovarian Cancer,166 only 32% of high grade ovarian 
cancer.167 ID4 is also highly expressed in Glioblastoma.168 In GBM, high ID4 expression 
was also observed in TCGA data sets, specifically in classical, neuronal and pro-neural 








2.12.4 ID4 DNA Alterations 
ID4, located in a 4 Mb region of the chromosome 6p22.3, is consistently 
amplified in bladder cancers with a positive outcome.169 On the contrary, genomic loss of 
ID4 is observed in Hodgkin’s Lymphoma.170 
Cytogenetic abnormalities resulting from chromosomal 6 translocations are also 
very common in hematologic malignancies. ID4 was demonstrated in one case of B-cell 
lineage acute lymphoblastic leukemia (ALL) with t(6;14) (p22;q32)171 indicating that ID4 
may act as an oncogene in some human leukemia cases through its ability to sequester 
specific B-cell transcription factors. In general, ID4 expression is down-regulated in 
ALL33, hence the translocation observed in one clinical case could be an isolated 
incidence in the backdrop of other genomic alterations.  
2.12.5 ID4 as a Tumor Suppressor 
Epigenetic silencing of ID4 in many cancers has prompted investigators to classify it as a 
tumor suppressor.30, 31c, 41, 161, 170, 172 (Figure 4) ID4 is epigenetically silenced in:  
Leukemia,30 AML,173 CLL,32 ALL,33 glial neoplasia,34 squamous cell carcinoma,35 gastric 
cancer,174  pancreatic cancer,175 colorectal,38 lymphoma,39 cholangiocarcinoma,31c 
esophageal,40 and lung cancer41. Meta-analysis in Oncomine database176 also suggested 
that ID4 expression is decreased in majority of cancers (Figure 7). 
2.12.6 ID4 and Prostate Cancer  
Previous studies from our laboratory strongly support the role of ID4 as a tumor 
suppressor in prostate cancer (PCa).172a, 177 Immuno-histochemical analysis of normal and 






specifically in prostate cancer but not in normal adjacent prostate glands177 (see also 
TCGA dataset in Figure 1 and PRAD in Figure 7).  Decrease in ID4 expression is stage 
dependent with majority of high grade tumor samples showing negligible ID4 expression 
while high ID4 expression is observed in the normal prostate tissue.177 We have shown 
that ID4 is expressed in PCa cell line LNCaP (low tumorigenic, androgen sensitive43), 
low in PC3, but not in C81 (androgen insensitive and more tumorigenic LNCaP 
derivative178), and DU145 cells.177 Furthermore, similar to other cancers, the decrease in 
ID4 expression in prostate cancer tissue and cell lines was attributed to promoter 
hypermethylation.172a, 177 Our study was further validated by Vinarskaja et al., who 
confirmed that ID4 promoter hypermethylation and down-regulation during prostate 
cancer progression.28 
Silencing of ID4 in LNCaP prostate cancer cells (LNCaP(-)ID4) results in a 
castration resistant phenotype, partly due to gain of de novo steroidogenesis.29 The 
LNCaP(-)ID4 cells also form tumors in castrated mice as compared to LNCaP cells.29 
These results suggested that ID4 is required to maintain the tumor suppressive function of 
AR whereas as loss of ID4 results in tumor promoter activity of AR.  These results could 
explain the ID4-/- mice prostate phenotype where AR is expressed at the levels similar to 
wild type mice but associated with PIN lesions.27 At the mechanistic level, ID4 may 
regulate the expression or function of AR co-regulators that may determine the final 








2.12.7 ID4 in Prognosis and Survival 
Inactivation of ID4 is also associated with poor differentiation and unfavorable 
prognosis in colorectal carcinoma.172c In breast cancer loss of ID4179 is associated with 
recurrence free survival, increased tumor relapse.172b AML patients with myelodysplastic 
syndrome (MDS) exhibited a significantly higher frequency of ID4 methylation with 
shorter survival.180  
In chronic myeloid leukemia, methylation of the ID4 promoter increases as the 
disease progressed from ‘chronic phase’ to ‘accelerated phase’ to ‘blast crises.’179 In a 
separate study ID4 was found methylated in 86% of acute leukemia patients and 100% in 
leukemia-relapse patients.31b ID4 expression was reduced by promoter methylation in 
95% of B-cell lymphoma samples and 100% of follicular lymphoma samples.  
2.12.8 ID4 and Angiogenesis 
Glioblastoma derived tumor cell expressing elevated levels of ID4 produce 
enlarged xenografts in immunosuppressed mice that were better vascularized than 
corresponding control tumors suggesting a novel pro-angiogenic function to ID4 
(mediated by Matrix GLA protein (MGP).181 In glial neoplasms down regulation of ID4 
is associated with inhibition of angiogenesis.34 In breast cancer cells increased ID4 
expression may also promote angiogenesis through stabilization of GRO-a and IL-8 








2.12.9 ID4 and Chemo-resistance 
High ID4 expression was shown to be responsible for chemo resistance to 
anticancer drugs in glioma stem cells (GSCs) by enhancing the expression of SOX2 by 
suppressing microRNA-9. SOX2 is a non-bHLH transcription factor known to play key 
role in development and maintenance of GSCs and is repressed by microRNA-9. The 
resulting ID4 mediated increased expression of SOX2 further induced ABC transporters 
such as ABCC3 and ABCC6 through direct transcriptional regulation resulting in 
chemoresistance of GSCs.182 
It is evident from the above studies that ID4 expression and association with 
various disease modalities even is same cancer types such as breast and glioblastoma is 
often conflicting. The analytical tools such as specific ID4 antibodies, RT-PCR strategy 
(given that ID4 gene is highly CG rich) and specific CpG islands in the promoter itself 
needs to be revaluated and validated. This is apparent from a prostate cancer study which 
demonstrated a positive correlation between ID4 overexpression with the Gleason score 
and metastatic progression.183 Use of highly specific ID4 antibodies, TCGA prostate 
adenocarcinoma (Figure 1) and Oncomine databases (Figure 7) clearly presented an 
inverse correlation between ID4 expression and prostate cancer.  Most of the ID4 
promoter methylation studies on cancers where ID4 is silenced have focused on the 
proximal promoter (surrounding the transcriptional start site) hence comparable and 
confirms epigenetic inactivation.  Cancer heterogeneity may also contribute equally to 






particularly in context of heterogeneity observed in many cancers. Decreased 
angiogenesis with better prognosis and increased survival in a subset of glioblastoma 
with low ID4 25b, 34 whereas high ID4 particularly in cells which are in close proximity to 
the vasculature181, 184 clearly supports an association between ID4 expression and cancer 
subtypes. A strong relationship between ID4 expression and cancer subtypes, particularly 
in GBM and breast is also evident from TCGA datasets (Figure 1). A clear discrimination 
between cancer subtypes (Breast and Glioblastoma), apparent from TCGA datasets 
(Figure 7) suggests that ID4 expression is a strong predictor of associated disease 
modalities.   
The contrasting expression of ID4 in various cancers (and sub-types) is suggestive 
of a complex molecular mechanism which could involve tissue/ stage/ sub-type specific 
interaction proteins, post-transcriptional modifications and regulatory mechanisms.   
2.13 Regulation of ID4 Gene Expression 
2.13.1 Transcriptional Regulation 
At least two functional elements located downstream of the TATA box have been 
identified in the ID4 promoter. The first, a positive regulatory element contains a 
consensus E-Box that binds the bHLH leucine zipper upstream stimulatory factor (USF). 
The second, a negative regulatory element is a GA motif recognized by Sp1 and Sp3 
transcription factors.185  
Interestingly, the predicted ER response element186 could result in the down-






Increased ID4 expression in TNBC164a therefore could in part be due to loss of ER. In 
sporadic breast tumors, ID4 is also inversely correlated with ER mRNA expression.160 In 
several tumor specimens, ID4 mRNA expression was lowest in samples expressing high 
levels of ER mRNA whereas treatment of ER positive breast cancer cells with estradiol 
resulted in decreased expression of ID4165 (also see Figure 7A). 
Our studies demonstrated that ID4 is regulated by the androgens in normal 
prostate epithelial cells and less metastatic prostate cancer cell line LNCaP.172a Ectopic 
ID4 expression also induced re-expression of androgen receptor and downstream 
transcriptional target PSA in otherwise androgen receptor negative prostate cancer cell 
line DU145.172a   
AR-mediated prostate tumorigenesis in mice expressing mutant androgen receptor 
(E231G) demonstrated negligible ID4 expression together with other signature genes to 
predict biochemical relapse in androgen receptor dependent prostate cancer.187 Taken 
together, these studies suggest that ID4 exists in positive feedback loop with AR but in a 
negative feedback loop with ER.  However, direct evidence that ER or AR binds directly 
to ID4 promoter is lacking. 
Other studies suggest that the tumor promoting role of ID4 in breast cancer can be 
linked to the ability of mutated p53 to regulate ID4 at the promoter level through specific 
binding sites mediated by E2F1 and p65.127 ID4 is also the downstream target of BMP4 
in neural progenitor cells and apparently mediates the inhibitory effects on 
oligodendroglial differentiation188 whereas ID4 dependent osteoblast differentiation is 






2.13.2 Epigenetic Regulation 
Gene silencing through promoter hypermethylation is the most widely accepted 
mechanism involved in the regulation of ID4 expression. ID4 promoter is CpG rich that 
spans the proximal promoter through entire exon 1 thus making this region highly 
attractive for epigenetic modifications. Several studies have not only extensively 
characterized the down regulation of ID4 expression through promoter hypermethylation 
in many cancers and cell lines, but have also linked ID4 expression to clinic-pathological 
variables, such as stage, tumor grade, age, cancer recurrence and poor prognosis such as 
in lung, bladder, breast and colorectal cancer 172b, 172c as discussed above. Demethylation 
of the breast cancer cell lines (BT20, MCF7 and T47D) by 5-Aza-2’-Deoxycytidine 
(AZA) and Trichostatin A172b and prostate cancer cell line DU145 by AZA172a resulted in 
clear re-expression of ID4 further supporting the hypermethylation as the primary 
mechanism involved in ID4 down-regulation in cancers.    
Studies in colorectal carcinoma demonstrated that ID4 promoter is regulated by Cdc4238, 
a small GTPase of the Rho family. High Cdc42 expression in many cancers189 including 
colorectal carcinoma, may suggest a role of cdc24 in ID4 promoter methylation.  How a 
protein involved in promoting cell cycle regulates epigenetic re-programming of the ID4 
promoter remains to be addressed.   
PRMT5, a type II protein arginine methyl-transferase which catalyzes mono- and 
di-methylation of arginine residues, is generally considered as an oncogene that promotes 
cell cycle. PRMT5 was shown to occupy the CpG rich islands in ID4 promoter resulting 






In cancer cells, high PRMT5 expression may tend to support its role in epigenetic 
silencing of ID4. However, in prostate cancer cells PRMT5 expression is primarily 
cytoplasmic and promotes growth. In contrast, PRMT5 is nuclear in benign prostate 
epithelial cells where it inhibits growth.190 Thus PRMT5 localization (predominantly 
cytoplasmic) in prostate cancer does not correlate with its role in ID4 methylation or 
association with CpG islands, which as one would expect to be in the nucleus. The 
transcription factor YY1 was also shown to inhibit ID4 transcription by recruiting histone 
deacetylase-1 to its promoter191 suggesting that histone acetylation may also play a role in 
regulating ID4 expression.   
EZH2 (enhancer of Zeste 2), part of the Polycomb repressor complex 2 (PRC2) is 
involved in epigenetic re-programming in both normal and disease states including 
cancer. EZH2 is specifically involved in covalent modification of histone tails, 
specifically tri-methylation (me3) of lysine 27 (K27) on histone 3 (H3) (H3K27me3), a 
repressive mark found on many gene promoters that are silenced.192 EZH2, as part of the 
PRC2 complex also recruits DNMTs (DNA methyl transferases) that in turn promotes 
DNA methylation at CpG islands (CGI) thus connecting the two key epigenetic 
repression systems.193 Increased EZH2 expression is also observed in many cancers194 
including prostate cancer.195 We recently demonstrated that ID4 is an EZH2 target gene 
in prostate cancer. Assembly of PRC2 complex initiated by increased recruitment of 
EZH2 on ID4 promoter increases the repressive H3K27me3 histone modification and 
recruits DNMT1/ 3a resulting in ID4 promoter hyper-methylation in DU145 prostate 






MCF7 and T47D)172b and prostate cancer (DU145)172a resulted in clear re-expression of 
ID4 by 5-Aza-2’-Deoxycytidine (AZA) a DNMT1 inhibitor  and HDAC inhibitor 
Trichostatin A. 
Epigenetic inactivation in many but not all cancers suggests that ID4 could be 
highly regulated in a tissue specific manner. Basal transcriptional machinery consisting of 
a subset of bHLH (USF1) transcription factors together with the assembly of tissue 
specific positive (AR, BMP4) or negative (ER) regulatory complexes could determine 
optimal ID4 transcription.  The binding of Sp1 to GC rich regions, which are targets of 
hyper-methylation, could be a rate-limiting step in the assembly of such transcription 
factor complexes on ID4 promoter that could eventually determine ID4 transcriptional 
output. 
2.13.3 Regulation of ID4 Expression by MicroRNA 
Recent studies have demonstrated that ID4 expression is also regulated by 
miRNAs. ID4 is repressed by miR342 (breast cancer cell line MDA-MB-231196, miR335 
(breast cancer cell line MCF7197 and senescence associated (SA) miR485-5p (fibroblast 
cell lines.198  
 2.14 Mechanism of Action of ID4 
Protein interaction studies have demonstrated that ID4 sequesters OLIG1 and OLIG2, 
members of class B bHLH proteins, which plays key roles in early oligodendrocyte 
specification and regulates oligodendrocyte differentiation.188 ID4 also promotes 






Recently, ID4 was also shown to interact with another bHLH transcription factor, 
Twist 1 in GBM.25b The sequestration of Twist-1 a putative tumor promoter also led to 
decreased MMP2 mediated invasion of glioblastoma derived cells. 
ID4 was found to down-regulate the expression of breast cancer susceptibility 
gene BRCA1164b suggesting a negative feed-back loop between BRCA1 and ID4.  
Surprisingly, BRCA1 induced the expression of ID4 in a study by Welcsh et al.165 
In ID4-/- mice, a decrease in ductal expansion and branching morphogenesis was 
attributed to activation of p38MAPK.148 Thus, ID4 may regulate major stress activated 
pathways through down-regulation of p38MAPK.  
A novel but un-expected mechanism of action of ID4 has recently emerged.  In a 
ChIP study, ID4 was found to be part of the transcriptional complex that could potentially 
regulate ERa and Foxa1. The lack of ID4 DNA binding domain in ID4 suggests that it 
most likely regulates transcription as part of a larger protein complex.199    
As opposed to the protein interaction network of ID1 and ID2, the regulatory 
network of ID4 remains to be fully explored.  Given the inverse association between ID1 
and ID4 in cancer, the ID4 regulatory network is expected to be unique and non-
overlapping.  The major questions that need to be addressed are whether ID4 negatively 
regulates ID1 dependent pathways.  If this is true then obviously the HLH independent 
mechanisms should be explored and/ or contributions of the non-HLH domains towards 
selective binding with bHLH and non-bHLH proteins between ID4 and other three ID 
proteins.  Moreover, the degree of overlapping functions between a subset of ID proteins 






structure/ function relationship. Recent data supporting the indirect interaction of ID4 
with DNA as part of the larger transcriptional complex is also interesting and opens an 
entirely novel dimension to the function of ID4.   
2.15 The role of ID4 in Cell Cycle and Proliferation 
Ectopic expression of ID4 blocks cell cycle and inhibits proliferation that is 
associated with increased expression of p21, and p27 in prostate cancer cell line 
DU145.172a The ID4 dependent cell cycle arrest appears to be primarily at S-Phase in 
DU145 and PC3 prostate cancer cell lines and not at G1 as would be expected from 
increased p21 and p27 expression.172a The block is S-phase appears to be due to decrease 
in the expression of E2F1 that is required for transition through S-phase.44 Loss of ID4 
also promotes progression into S-phase in neuronal early cortical progenitor cells151 and 
LNCaP prostate cancer cell lines. Epigenetic knockdown of ID4 through promoter 
hypermethylation in colon carcinoma by Cdc42, a member of Rho GTPases family may 
be required for cell cycle progression.38 Nevertheless, these results suggest that unlike 
ID1, ID2 and ID3, the expression of ID4 is not associated with progression of cell cycle 
and points towards the role of ID4 in promoting differentiation in specific cell types since 
both these processes are largely mutually exclusive.   
ID4 can also drive the malignant transformation of astrocytes via de-regulation of 
cell cycle and differentiation through the up-regulation of cyclin E and activation of 
Jagged-Notch1 signaling but only in primary murine Ink4a/Arf-/- astrocytes.184 Increased 
ID4 expression168 and deletion of the INK4a-ARF locus is also found in majority of 






upstream regulator of ID4 in a subset of gliomas. Whether ID4 itself drives the 
expression of Ink4a/ Arf or vice versa to block cell cycle could be an interesting avenue 
to investigate. 
2.16 ID4 in Therapeutics 
Overwhelming evidence suggests that ID4 is epigenetically silenced in many 
cancers.  Hence therapeutic strategies which alter the cancer epigenome via inhibition of 
DNMT1 such as by AZA201 are viable strategies. Alternatively, mechanisms involved in 
regulating ID4 levels at the transcriptional level such as those involving ER and AR 
could be exploited to elevate ID4 levels in breast and prostate cancer.   A study recently 
demonstrated that treatment cells by arsenic trioxide (ATO) reversed the hyper-
methylation of ID4 promoter and decreased proliferation of Raji cells.202  The specificity 
of this treatment on ID4 promoter however remains to be investigated.  
A tumor-penetrating nano-complex (TPN) comprising of siRNA complexed with 
a tandem tumor-penetrating and membrane-trans-locating peptide, which enables the 
specific delivery of siRNA deep into the tumor parenchyma was employed in vivo to 
evaluate the role of ID4 as an oncogene167 in tumors, where ID4 expression is elevated 
such as those of the ovary. Treatment of ovarian tumor-bearing mice with ID4-specific 
TPN suppressed growth of established tumors and significantly improved survival.  
2.17 Conclusion  
It is evident that ID4 shows divergence from the other ID family members during 






have clearly established the essential role of ID4 in development that is not compensated 
by other ID proteins. Overall, the role of ID4 in cancer appears to be that of a tumor 
suppressor that is largely based on its epigenetic silencing in majority of cancers. The 
expression of ID4 in limited cancer types (GBM) is associated with favorable prognosis 
further supporting the role of ID4 as a putative tumor suppressor. How ID4 acts as a 
tumor suppressor is an open question and should be the major focus of future studies. The 
other major question that remains to be addressed is the mechanism by which ID4 acts as 
a tumor promoter in limited cancer sub-types such as TNBC, basal cell carcinoma of the 
breast and ovarian cancer. Interaction of ID4 with bHLH proteins such as OLIG and 
TWIST and cross-talk with BRCA1, p38MAPK and Notch signaling pathway may 
provide a significant insight into the mechanism of action of ID4 that needs to be further 
explored. The lack of a DNA-binding domain and unique sequence of ID4 (Alanine and 
Proline rich domains that support protein interactions) also suggest that ID4 may act as a 
major hub in protein–protein interaction networks, possibly as a putative co-chaperone. 
These interactions may help unravel the complex biology of ID4 in development and 
cancer. The strong anti-cancer effect of ID4 in prostate cancer suggests that mechanisms 









MATERIALS AND METHODS 
 
3.1 ID4 over-expression and Silencing in Prostate Cancer Cell Lines 
The prostate cancer cell lines LNCaP, DU145 and PC3 were purchased from 
ATCC and cultured as per ATCC recommendations. Human Id4 was over-expressed in 
DU145 cells as previously described.172a ID4 was stably silenced in LNCaP cells using 
gene specific shRNA retroviral vectors (Open Biosystems #RHS1764 -97196818, -
97186620 and 9193923 in pSM2c, termed as Id4shRNA A, B and C respectively).  The 
cells transfected with non-silencing shRNA (RHS1707) was used as control cell line. 
Transfections and selection of transfectants (puromycin) were performed as suggested by 
the supplier.  Successful ID4 gene silencing was confirmed by qRT-PCR, Western blot 
analysis, and ICC.   
3.2 RNA Extraction 
Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA) as described 
previously. The final RNA pellet was re-suspended in diethylpyrocarbonate (DEPC)-






3.3 Reverse Transcriptase 
 RNA (2 μg) was reverse transcribed in a final volume of 25 μl as per standard 
protocols (RT-Mix: 1.25 mM each of dNTP's; 250 ng oligo dT (Promega, Madison, WI), 
10 mM dithiothreitol, and 200 U MMLV reverse transcriptase (Invitrogen) in the MMLV 
first-strand synthesis buffer (Invitrogen)). The RNA was denatured for 10 min at 65°C, 
and then cooled on ice before addition of RT mix and enzyme. The reverse transcriptase 
reaction was carried out at 42°C for 1 h and 95°C for 5 minutes.  Samples were stored at -
20°C until analysis. 
3.4 Quantitative Real Time PCR (qRT-PCR) 
qRT-PCR was performed as described previously using gene specific primers 
(Table 1) on RNA purified from cell lines.203 
Table 1. qRT-PCR and ChIP Primers Used in the Study 
 
 
PCR primers Forward (5' ) Reverse (5') 
Id4 CCCTCCCTCTCTAGTGCTCC GTGAACAAGCAGGGCGCA 
GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC 
PUMA CTGTATCCTGCAGCCTTTGC ACGGGCGACTCTAAGTGCT 
BAX CAG AGG CGG GGT TTC ATC AGC TTC TTG GTG GAC GCA T 
p21 GCCATTAGCGCATCACAG TGCGTTCACAGGTGTTTCTG 
p53 GCTCGACGCTAGGATCTGAC GCTTTCCACGACGGTGAC 
CHiP Primers spanning the p53 response 
elements  
  
p21 Chip GTGGCTCTGATTGGCTTTCTG TCCTTGGGCTGCCTGTTTTCAG 
BAX chip TAATCCCAGCGCTTTGGAAG GCTGAGACGGGGTTATCTC 






3.5 Protein Extraction 
 Total cellular proteins were prepared from cultured prostate cancer cell lines 
using M-PER (Thermo Scientific).172a Protein samples were quantitated using the The 
Bio-Rad DC Protein Assay according to manufacturer protocol. A standard curve was 
determined using BSA and sample absorbance read at 750 nm. Samples were 
concentrated in 30 ug/ul volume and then mixed 1:1 with 2X Sample Buffer. 
3.6 Western Blot Analysis  
30 ug of total protein was size fractionated on 4-20% SDS-polyacrylamide gel 
(5% for CBP/p300 western blotting) and subsequently blotted onto a nitrocellulose 
membrane (Whatman). The blotted nitrocellulose membrane was subjected to western 
blot analysis using respective protein specific antibodies (Table 2). After washing with 1x 
PBS, 0.5% Tween 20, the membranes were incubated with horseradish peroxidase (HRP) 
coupled secondary antibody against rabbit IgG and visualized using the Super Signal 
West Dura Extended Duration Substrate (Thermo Scientific) on Fuji Film LAS-3000 
Imager. 
 








ID4 Aviva 1:1200, 1:200 
ID4 BioCheck 1:1000 





BAX Cell Signaling 1:1000 

















3.7 Proliferation Assay   
Cell proliferation analyses were performed using 3-(4, 5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. LNCaP+NS and LNCaP-Id4 cells were 
seeded in 96-multi well plates at a density of 5 x 105 cells/ well without serum overnight. 
Cells were then cultured for 72 hrs.  MTT assay was performed using CellTiter 96 Non-
Radioactive Cell Proliferation Assay kit (Promega) following manufacturer’s 
instructions. 
3.8 Statistical Analysis (Proliferation) 
 Data was analyzed by SPSS 13.0 statistics software.  Experimental data is 
presented as means ± the standard deviations.  A p-value of <0.05 will be considered 
statistically significant.  
p21                Cell Signaling 1:1000 





MYC Cell Signaling 1:1000 
RNA Pol II Millipore  
      Global Acetylated lysine  Cell Signaling 1:1000 
K320 Millipore 1:1000 
K373 Abcam 1:1000 
goat anti-rabbit 
Secondary Antibody Millipore 
1:10000 
PDH Cell Signaling 1:250 
    ICC secondary antibodies  Cell Signaling    
DyLight 594 goat 
anti-mouse (red) Thermoscientific 
1:200 
DyLight 488 goat 
anti-rabbit (green) Thermoscientific 
1:200 
DyLight 594 goat 
anti-rabit (red) Thermoscientific 
1:200 
DyLight 488 goat 







3.9 Co-Immunoprecipitation (ChIP) 
To detect the protein-protein interactions, co-immunoprecipitation was performed 
using protein A coupled to magnetic beads (Protein A Mag beads, GenScript) as per 
manufacturer’s instructions.  Briefly, protein specific IgG (anti-p53 or -ID4, Table 3) was 
first immobilized to Protein A Mag Beads by incubating overnight at 40C.  To minimize 
the co-elution of IgG following immuno-precipitation, the immobilized IgG on protein A 
Mag beads was cross-linked in the presence of 20mM dimethyl pimelimidate 
dihydrochloride (DMP) in 0.2M triethanolamine, pH8.2, washed twice in Tris (50mM 
Tris pH7.5)  and PBS followed by  final re-suspension and storage in PBS .  The cross-
linked protein specific IgG-protein A-Mag beads were incubated overnight (4C) with 
freshly extracted total cellular proteins (500 µg/ml).  The complex was then eluted with 
0.1 M Glycine (pH 2-3) after appropriate washing with PBS and neutralized by adding 
neutralization buffer (1 M Tris, pH 8.5) per 100 µl of elution buffer.  
3.10 Electrophoretic Mobility Shift Assay (EMSA) 
The nuclear proteins from respective cell lines were prepared using the nuclear 
extraction kit from Affymetrix (AY2002) according to the manufacturer’s instructions.  
1µl of nuclear proteins were used in an EMSA reaction using Biotin end labeled p53 
double stranded oligonucleotide (Affymerix, AY1032, p53 EMSA kit containing the p53 
response element 204).  The nuclear proteins and labeled oligonucleotide or excess 
unlabeled oligonucleotide were incubated for 20 min at room temperature, separated on 






detected following manufacturer’s instructions.  The EMSA using LNCaP+NS cells with 
wild type p53 and p53 null PC3 was used as positive and negative controls, respectively.  
3.11 p53 Activity Assay 
 p53 DNA binding activity and quantitation on nuclear extracts was performed by 
capturing p53 with double stranded oligonucleotides containing a p53 consensus binding 
site immobilized in a 96 well format (TF-Detect p53 Assay, Genecopoeia) followed by 
detection with p53 specific antibody in a sandwich ELISA based format according to 
manufacturer’s instructions (essentially a quantitative super-shift assay).   
3.12 Transient Transfections and Luciferase Reporter Gene Assay 
Cells were cultured in 96-well plates to 70-80% confluency and transiently 
transfected by mixing either PG13-luc (containing 13 copies wt p53 binding sites,205 
Addgene) or MG15-luc (containing 15 mutant p53 binding sites,205 Addgene) with 
pGL4.74 plasmid (hRluc/TK: Renilla luciferase, Promega) DNA in a 10:1 ratio with 
FuGENE HD transfection reagent (Promega) in a final volume of 100 ul of Opti-MEM 
and incubated for 15 min at room temperature. The transfection mix was then added to 
the cells.  After 24 h, the cells were assayed for firefly and Renilla luciferase activities 
using the Dual- Glo Luciferase reporter assay system (Promega) in LUMIstar OPTIMA 
(MHG Labtech). The results were normalized for the internal Renilla luciferase control. 
3.13 Apoptosis Assay  
 Apoptosis was quantitated using Propidium Iodide and Alexa Fluor 488 
conjugated Annexin V (Molecular Probes) and  dual-sensor MitoCasp (Cell Technology) 






3.14 Statistical Analysis (Apoptosis) 
Quantitative real time data was analyzed using the delta delta Ct method.  The 
ChIP data was analyzed using % chromatin (1%) as input (Life Technologies).  Within 
group Student’s t-test was used for evaluating the statistical differences between groups.  
3.15 Mutagenesis of p53 
 Mutagenesis of p53, the retroviral p53 vector previously described was 
manipulated via mutation induced by site-directed mutagenesis mimicking DU145 cells 
that harbor mutant p53 (P223L and V274F).207 Also, hotspot mutations of p53 found any 
many cancers (R273H and R175H)208  purchased from Addgene, Inc , pCMV-Neo-Bam 
p53 R175H was a gift from Bert Vogelstein (Addgene plasmid #16436)  as well as 
pCMV-Neo-Bam p53 R273H(Addgene plasmid # 16439).209 
3.16 Immunohistochemistry (IHC) 
Slides were processed through standard protocols. Following antigen retrieval 
(autoclave in 0.01 M sodium citrate buffer pH 6.0 at 121C/20 psi for 30 min), the 
peroxidase activity was blocked in 3% H2O2 and nonspecific binding sites blocked in 
10% Goat serum. The blocked sections were incubated overnight at 4°C with respective 
protein specific primary antibodies followed by incubation with secondary antibody for 1 
hour. The slides were stained with DAB for 2 min, counterstained with haematoxylin and 
mounted with Immuno-mount (Thermo Scientific), examined and photo-micrographs 
taken using the Zeiss microscope with an AxioVision version 4.8 imaging system. All the 
antibodies were mono-reactive, that is a single reactive band was observed in western 






3.17 Quantitative Senescence associated (SA)-β-galactosidase assay  
 The cells were cultured in six well plates with respective media. The cells at 60-
70% confluency were stained for senescence associated-β-galactosidase (SA-βgal) 
staining kit (Cell signaling) as per manufacturer’s instructions. At least 15 representative 
fields were randomly selected for the quantitation of the percentage of SA-βgal positive 
cells. The images were captured in both phase contrast and bright field to better visualize 
cellular details. 
3.18 The structures of Wild Type and Mutant p53 
 The wild type p53 core domain (residues 94-269) structure 1TSR5  was obtained 
from the Protein Data Bank (PDB), a widely used portal for biological macromolecular 
structures 210. The 1TSR represents the X-ray crystal structure of a wild type core domain 
p53 -DNA complex at 2.2 A resolution with a crystallographic R factor of 20.5%.5 The 
DNA binding domain of p53 consists of a beta sandwich that serves as a scaffold for two 
large loops and a loop-sheet-helix motif. The two loops, which are held together in part 
by a tetrahedral coordinated zinc atom, and the loop-sheet-helix motif form the DNA 
binding surface of p53. We therefore used 1TSR as a framework to study p53 mutations 
that fall within the DNA binding domain. The base 1TSR peptide sequence was used to 
introduce prototype p53 mutations: R175H, R273H, P223L, and V274F. The widespread 
R175H and R273H were used as hot spot gain of function p53 mutations while P223L, 
and V274F were used a weak temperature sensitive mutants found in DU145 prostate 







3.19 Molecular Dynamics Simulation 
In collaboration with the physics department at Clark Atlanta University, we 
performed molecular dynamic simulations of 1TSR (wild type) and core domain mutants 
using the CHARMM (Chemistry at HARvard Macromolecular Mechanics), an all-atom 
empirical energy function force field.211 The CHARMM force field treats interactions of 
amino acids with bonded and non-bonded terms. It is worth noting that in order to 
properly characterize the relevant interactions, it is necessary to include explicit solvent. 
For this reason, our MD calculation results were rectified with simulations with explicit 
water. 212 Computational simulations largely utilize the atomic description of 
biomolecules. However, many studies have shown that molecular systems may have 
diverse conformations due to large numbers of degrees of freedom around chemical 
bonds, leading to a plethora of local minima conformations.213 Biological function is 
associated when the structure which is in the proximity of a global energy minimum. In 
an effort to optimize the system, we used simulated annealing with repeated search cycles 
with various initial conformations using NAMD (NAnoscale Molecular Dynamics) and 
subsequent visualization in VMD (Visual Molecular Dynamics). NAMD was developed 
by the Theoretical and Computational Biophysics Group in the Beckman Institute for 
Advanced Science and Technology at the University of Illinois at Urbana-Champaign.212  
NAMD is a parallel molecular dynamics platform (on Charm++) for high performance 
simulation of large biomolecules systems. Shown in supplementary figures 2a-2h are the 






serves as an optimization technique that readily converges energy of biomolecules after 
20 to 30 cycles.  
The potential energy of core domain 1TSR and mutants was calculated in a given 
conformation as a sum of individual energy terms of bonded and non-bonded 
interactions.211b, 212 The following assumptions were made to address the effect of 
mutation in a confirmation: 1) Changing a residue in a wild type affects overall bonding, 
2) Non-bonded terms such as electrostatic, van der Waals and polarization are 
independent of mass, and 3) Bonded terms such as energy of stretch, bending and torsion 
depend on the molar mass of residues. A bond was considered as a spring with its own 
equilibrium length 𝑟0 (in our assumption the center of mass of a residue is 𝑟0 ). The 
energy that is required to stretch or compress a bond between two atoms or to bend a 
bond from its equilibrium angle depends on the constant of the spring constant. 
Therefore, the overall energy of bending and stretching depends on molar mass while a 
mutation is considered similar to changing the spring in a harmonic motion. Periodic 
Fourier function was used to represent the energy of torsions between particles based on 
molecular dynamics. The interaction mode 𝑣𝑛 was defined as 𝑣𝑛 ∝
1
2𝑚
 , where m is the 
molar mass of the residue. Therefore the changes in energy () can be considered as the 
effect of molar mass of residue (m) harmonious to changes in energy of stretch, bending, 
and torsion in a protein by: 𝛽 ∝ 𝑚 
We also assumed at the minimum that mutating a residue in a protein may have 











𝑛=1  , where  𝑚𝑛 is the molar mass of the nth residue. As such we can 














where the nominator and denominator denote the reciprocal effective mass for the 
mutated residue and wild type, respectively. 








where the central segment can be either a mutated or wild type residue. As such, we can 
characterize the relative change of the effective mass as  
𝜇 = 𝑚(mutated)/m(wild type). 
Thus, 𝜇 is dimensionless and characterizes the correlation between the mutated 









4.1 ID4 Regulates Wild-type and Mutant p53 
4.1.1 Expression of ID4 in Prostate Cancer cell Lines 
The cellular and molecular alterations of epithelial cells in the prostate and their 
microenvironments during cancer development are complicated, and it is difficult to use a 
single cell line to study these changes and also to study the pathophysiological effects 
mediated by p53. Cell lines that will be utilized herein are derived from different Prostate 
Cancer (PCa) hosts and have their own characteristics that may be representative of 
different stages of PCa. LNCaP cells, isolated from a human PCa lymph node 
metastasis215, are positive for ID4 and have wild-type p53; DU145 cells, derived from a 
brain metastasis of human PCa216, harbors a mutant form of p53 and ID4 has been 
reported to be epigenetically silenced; PC3 cells isolated from a human PCa bone 
metastasis with high malignancy58, is p53-null and has endogenous levels of ID4. 
ID4 is undetectable in DU145 cells due to promoter hyper-methylation.217 In 
contrast, ID4 was expressed in LNCaP cells due to promoter hypo-methylation.  These 






ID4. Lastly, we wanted to use the highly metastatic cell line, PC3 to investigate possible 
ID4-p53 cross-talk. Since, PC3 cells are null for p53 and express ID4, we overexpressed 
wild-type p53 as well as mutant p53 via site-directed mutagenesis mimicking DU145 
p53mutations (P223L and V274F) and p53-hotspot mutations (R273H and R175H) 
(Figure 8B,C) a gift from Bert Vogelstein’s group (Table III) to study possible cross-talk 
of ID4 and p53 mediated pathways. In the same manner as our LNCAP-ID4 cellular 
model (Figure 9), we stably silenced ID4 in PC3 cells as well created and PC3+p53 
(wild-type and mutant) overexpression model (+/-) ID4 (Figure 9). Herein, our p53 
overexpression (P223L and V274F: DU145 cells) (R175H and R273H: hotspot p53 
mutants) model system will be referred to as wild type and mutant p53 to represent both 
DU145 and hotspot p53 mutants as aforementioned.                      
Table 3. PC3 Wild type and Mutant p53 Overexpression Model in the Presence and 
Absence of ID4             
 
 
Figure 8. (A) Schematic view of p53 domain with mutations in DBD domain 






Two different retroviral shRNA vectors (vectors A and C) were used to silence 
ID4 (Figure 9) in LNCaP and PC3 cells. The experiments reported here were performed 
on stable knockdown of ID4 in LNCaP and PC3 cells using vector A (LNCaP-ID4) (PC3-
ID4). p53 (wild type and mutant) over-expression in PC3 cells ( Figure 9) and their 
respective vectors were used for all subsequent experiments. A non-silencing control 
vector was also transfected into LNCaP and PC3 cells (LNCaP+NS) (PC3+NS). 
Expression of ID4 was measured by quantitative PCR and western blotting (Figure 9). 
 
D         
        
                                                                                         
Figure 9. Stable knockdown of ID4 by retroviral shRNA in LNCaP  and PC3 cells (retroviral vectors A 
and C).  (A) Real time quantitative polymerase chain reaction for ID4 expression in LNCaP (NS, non-
specific) following transfection with ID4shRNA vectors A and C and non-silencing shRNA (NS) (***: 







ID4 specific shRNA (-ID4, vector A).  (C) Immuno-cytochemical analysis of stable knockdown of Id4 
expression in LNCaP cells (LNCaP-ID4, vector A) as compared to cells with non-specific shRNA 
(LNCaP+NS).  The red staining indicates ID4 expression (DyLight 594).  ID4 expression in DU145 cells 
stably transfected with Id4 expression vector (DU145+ID4) as compared to DU145 cells transfected with 
empty vector (DU145+NS).  The green staining represents Id4 (DyLight 488).  DAPI was used to stain the 
nuclei (blue) in both LNCaP and DU145 cells.  Representative images are shown. (D) Western Blot 
analysis of ID4 expression with non-specific shRNA (NS) and ID4 specific shRNA (-ID4, vector A) and 
p53 expression (DU145 specific p53 mutants: P223L and V274F) in PC3 cells via site-directed 
mutagenesis. (E) Western blot analysis of ID4 expression with non-specific shRNA (NS) and ID4 specific 
shRNA (-ID4, vector A) and p53 expression (Hotspot p53 mutants: R175H and R273H).  
 
4.2 ID4 Effects on Proliferation and Gene Profile upon Silencing of ID4 in LNCaP 
Cells  
 
Upon ID4 silencing we investigated proliferation in LNCaP cells via a MTT 
assay, which measures the rate of cell proliferation. We observed that the rate of 
proliferation nearly doubled after ID4 silencing (Figure 10A). This data suggests loss of 
ID4 promotes increased proliferation and suggests that in the absence of ID4 cellular 
apoptosis could be adversely affected as well.   
After observing the effect of ID4 on proliferation, we investigated proliferation 
marker cylin dependent kinase inhibitor p27, which could provide insight into the 
molecular mechanism by which ID4 may effect proliferation. The expression of p27 was 
detected by q-PCR (Figure 10B). The expression of p27 is decreased by 9-fold upon loss 
of ID4, as compared to LNCaP+NS controls.  Thus, the increase in proliferation may be 
due deregulation of p27.  Also, this phenomenon could have an adverse effect on 
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Figure 10. Loss of ID4 promotes proliferation. (A) There is an increase in the proliferation of LNCaP-Id4 
cells by fold change of 2. Data is statistically significant. Each bar represents Mean ± SD from a 
representative experiment. (P< 0.05). (B) The mRNA expression of cyclin dependent kinase p27 was 
decreased upon loss of ID4.  p27 has been implicated in cell proliferation 
  
 
4.3 ID4 Effects on p53-mediated Apoptosis  
  
A significant increase in apoptotic cells was observed in DU145+ID4 (64+3.3%, 
P<0.001, Figure 11A) cells as compared DU145 cells (24+5.1%, Figure 11A) whereas a 
number of cells undergoing apoptosis decreased in LNCaP-Id4 (10.5+2.3%) as compared 
to LNCaP (47.2+6.5%) cells (Figure11A). Also, we observed that p53 promoted basal 
apoptosis in an ID4 dependent manner in PC3 cells where both wild type and mutant p53 
had been overexpressed  (Figure11B). We observed a marked increased in apoptosis in 
PC3+wtp53 (42.2+3.2%) as compared to control pcDNA (9.9+1.3%) as well observing 
significant apoptosis in mutant forms of p53 (PL-34.6+6.2%, VF-32.0+4.0%, VFPL- 






p53 overexpression did not induce apoptosis at the rate of wild-type p53 given the mutant 
status of p53 (Figure 11B). Conversely, we observed the opposite effect took place upon 
ID4 silencing. We found that ID4 silencing reduced the rate of apoptosis amongst both 
wild type p53 (27.5, 6.2%) and mutant p53 (PL-6.7,3.0%, VF- 7.7, 5.6%, VFPL- 13.5, 
6.2%) overexpression models compared to controls NS (14.2, 2.9%) and 
PC3+ID4shRNA (10.2, 2.2%) (Figure 11B). We also investigated the rate of apoptosis 
when p53 hotspot mutations (R175H and R273H) were overexpressed (Figure 11C). We 
observed that both hotspot mutants did induce apoptosis (R175H-20.6+7.6%, R273H- 
15.0, 4.6%) compared to wtp53 (36.4, 5.9%) and negative control pcDNA (10, 2.9%) 
(Figure 11C). As expected the rate of apoptosis with mutant p53 was significantly lower 
as compared to that observed with wild type p53. However, significant rates of apoptosis 
with mutant p53 were observed as compared to the negative control pcDNA (Figure 
11C). Thus, the results indicate that p53 promotes apoptosis in an ID4 dependent manner 
in PC3 cells. We also observed that upon ID4 silencing in PC3 cells we observed a 
similar pattern of apoptosis as compared to basal levels of apoptosis in PC3 cells with 
endogenous ID4 as previously shown.218 We observed an increase in apoptosis in wild-
type p53 (27.5, 8.6%) compared to controls NS (9.8, 2.1%) and PC3+ID4shRNA (8.7, 
3.0%), but there was a significant decrease of apoptosis compared to the PC3+wtp53 
(36.4, 5.9%) with endogenous ID4. We also observed a significant decrease in apoptosis 
compared to wtp53+ID4shRNA in p53 hotspot mutants upon silencing of ID4 as well 






in apoptosis with regard to the hotspot p53 mutant R273H compared to overexpression 
with endogenous ID4 likely due to R273H a classified DNA contact mutant.  
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Figure 11. ID4 promotes p53-mediated apoptosis. (A) Percent cells undergoing apoptosis was determined 
by propidium iodide and Annexin V staining followed by flow cytometery.  Significant increase in 
apoptosis (***: P<0.001) was observed in DU145 cells over-expressing ID4 (D+ID4) when compared with 
DU145 cells alone (D).  A significant decrease in apoptosis was observed in LNCaP cells that lacked ID4 
(L-ID4) as compared to LNCaP cells (L, ***: P<0.001). (B) A significant increase in apoptosis (***: 
P<0.001) was observed in PC3+pcDNA versus wtp53 and p53 mutants (p53 mutants: P223L and V274F) 
“a”: significant difference between wtp53 versus mutant p53. A significant decrease in apoptosis was 
observed in PC3 cells that lacked ID4 (PC3-ID4) compared PC3 cells wit wtp53 and p53 mutants. (C) A 
significant increase in apoptosis (Hotspots: R175H and R273H) (***: P<0.001) was observed in 
PC3+pcDNA versus wtp53 and p53 mutants. “a”: significant difference between wtp53 versus p53 
mutants. A significant decrease in apoptosis was observed in PC3 cells that lacked ID4 (PC3-ID4) 









4.3.1 ID4 Effects on p53 Mediated Apoptosis Gene Profile upon ID4 Silencing in 
LNCaP and PC3 Cells as well as Overexpression of ID4 in DU145 Cells 
 
After observing the effect of ID4 on apoptosis, we investigated known target 
genes of p53 to elucidate the molecular mechanism by which ID4 may promote apoptosis 
via p53. The target genes studied were p21, PUMA, and BAX.  BAX expression and/or 
PUMA dependent dissociation of BAX from Bcl-2 promotes translocation of BAX to 
mitochondria resulting in decreased mitochondrial membrane potential.219 The expression 
of pro-apoptotic BAX and PUMA increased in DU145+ID4 cells whereas a 
corresponding decrease in BAX and PUMA was observed in LNCaP-ID4 cells at the 
transcript (Figure 12A) and protein (Figure 12B) level as compared to DU145 and 
LNCaP+NS cells respectively (Figures 12A,B).  These results suggest the role of ID4 in 
promoting apoptosis through increased expression of BAX and PUMA.  Apoptotic 
stimuli induce BAX activation, characterized by translocation and multimerization on the 
mitochondrial membrane surface resulting in exposure of an amino terminal epitope 
recognized by the confirmation specific monoclonal antibody BAX 6A7.220 Co-
localization of BAX (BAX 6A7 antibody) with mitochondrial PDH (pyruvate 
dehydrogenase) demonstrated that BAX undergoes conformational change and 
translocates to the mitochondria in DU145+ID4 and LNCaP+NS cells (Figure 12B) but 
not in DU145 and LNCaP-ID4 cells possibly due to undetectable levels of BAX (Figure 
12B).   
As expected, decreased apoptosis in part due to loss of BAX and PUMA 






LNCaP+NS cells as previously shown.218 A similar relationship between ID4 and p53 
expression was not observed in DU145 cells.  Unlike wt-p53 in LNCaP+NS cells, the 
DU145 cells harbor mutant p53.  The two mutations (P223L and V274F) are within the 
DNA binding domain that results in a transcriptionally inactive form of p53.221 Mutant 
p53 protein generally accumulates at high levels due to loss of regulatory mechanisms as 
seen in DU145 cells.222 
We also investigated the expression of CDKN1A (p21), which is also a well 
characterized p53 target gene.223 Increase in the expression of p21, (9 fold as compared to 
DU145) (Figure 12A), in addition to PUMA and BAX further consolidated our 
observations that mutant p53 in DU145+ID4 cells may have gained transcriptional 
activity through site specific DNA binding in the respective promoter elements. 
To further elucidate the molecular mechanism by which ID4 promoted apoptosis 
in LNCaP and DU145 cells, p53 target genes: p21, PUMA, and BAX were also used to 
investigate ID4 mediated apoptosis when wild-type and mutant p53 were overexpressed 
in PC3 cells. Investigation of p53 in PC3 cells, which have endogenous ID4 served as the 
model to examine the transactivation potential of p53 as shown when ID4 was 
overexpressed in DU145 cells (Figure 12C).  
As aforementioned study of CDKN1A (p21), which is a well characterized p53 
target gene 223 was investigated.  Increase in the expression of p21, in addition to PUMA 
and BAX (Figures 12C, compared to PC3) further consolidated our observations that 
wild-type p53 as well as over-expressed mutant p53 in PC3 cells may have gained 






downstream targets of p53 when hotspot mutants: R175H and R273H that were 
transfected into PC3 cells (Figure 12D). This finding was critical to this study as this 
suggested ID4 has an effect on well-established p53 mutations, suggesting that ID4 may 
play a role in an array of different p53 mutants. Conversely, we observed the opposite 
effect upon silencing of ID4 in PC3 cells (DU145-p53 mutants and hotspot mutants). The 
expression of p21, PUMA, and BAX were down-regulated compared to PC3 cells with 
endogenous ID4 (Figure 12D). 
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Figure 12. Gene expression profile following ID4 silencing and wild type and mutant p53 overexpression 
in PC3 cells. (A) Real time quantitative analysis of p21, BAX and PUMA expression in D, D+ID4, L and 
L-ID4 cells.  The mean+SEM of three experiments in triplicate are shown.  The delta delta Ct (normalized 
to GAPDH) between D and D+ID4 (D normalized to 1, designated as “a’) and between L and L-ID4 (L 
normalized to 1, designated as “b”) is shown (*: P<0.001). (B) Western blot analysis of p21, BAX, 
confirmation specific BAX (BAX6A7) and PUMA in D, D+Id4, L and L-Id4 cells.  GAPDH was used as 
loading control. (C,D) Representative western blots of three different experiments are shown. Western blot 
analysis of p21, BAX, and PUMA in PC3 cells transfected with wild type and mutant p53 (C) Transfection 







4.3.2 ID4 Promotes p53-mediated UV-Induced Apoptosis 
p53 plays a crucial role in mediating DNA damage responses.224 UV treatment 
was utilized to activate the DNA-damage pathway mediated by p53. The PC3 cellular 
(wild-type and mutant p53) (+/-) ID4 model was used to investigate the DNA damage 
pathway via UV radiation treatments at 40 J/m2. Similarly to the previous study, where 
we examined apoptosis at the basal level in PC3 cells with p53 overexpression (wild-type 
and mutant) (+/-) ID4, we sought to investigate apoptosis in the same manner after UV-
radiation. After UV-radiation we observed a significant increase in apoptotic cells in PC3 
cells with overexpressed wild type p53 (42.2,6.2%) and mutant p53 (PL- 34.6,11.2%, 
VF- 32.0, 4.6%, VFPL-21.6, 8.9%) compared to control pcDNA (9.9, 2.2%) (Figure 
13A). Upon ID4 silencing in PC3 cells we observed a reduced rate of apoptosis compared 
to PC3 cell lines with endogenous ID4. When ID4 was silenced the rate of apoptosis in 
wild-type p53 was (39.7, 8.9%) and mutant p53 (PL- 22.3, 8.6%, VF- 23.1, 7.6%, VFPL- 
18.6, 6.9%) (Figure 13B). Thus, this data suggests that p53 (wild-type and mutant) 
promoted apoptosis after UV-radiation treatment in an ID4 dependent manner in PC3 
cells.  
The results observed in the UV induced apoptotic study led us to investigate the 
molecular mechanism by which ID4 promotes apoptosis. Subsequently, cellular protein 
was extracted and investigated for the expression of proliferation marker cyclin 
dependent kinase inhibitor p21 and apoptotic markers PUMA, and BAX in PC3 cells 
harboring wild-type p53 and p53 mutants (+/-) ID4 via western blot analysis to 






BAX were decreased upon loss of ID4, as compared to PC3 cells harboring wild type and 
mutant p53 in the presence of ID4 (Figure 13C). Thus, the decrease in cell cycle regulator 
(p21) and apoptotic markers (PUMA and BAX) upon silencing of ID4 could suggest that 
ID4 plays a critical role in p53 transactivation and the ability of p53 to effect both 
apoptosis and senescence.  
 
Figure 13. ID4 promotes UV-induced p53-mediated apoptosis.  (A) A significant increase in apoptosis 
(***: P<0.001) was observed in PC3+p53 and PC3+mutp53 (p53 mutants: P223L and V274F) compared 
with PC3 cells alone when treated with UV-radiation. (B) A significant decrease in apoptosis was observed 
in PC3 cells that lacked ID4 (PC3-ID4) compared PC3 cells (PC3, ***: P<0.001) when treated with UV-
radiation. (C) Western blot analysis of p21, BAX, and PUMA in PC3 cells transfected with wild type and 
mutant p53. GAPDH was used as loading control.  Representative western blots of three different 













4.4 ID4 Promotes p53-mediated Senescence  
Microscopic examination of PC3 + wtp53 cells revealed visibly enlarged 
morphology and accumulation of cytoplasmic aggregates as compared to mutant forms of 
p53 overexpressed in PC3 cells (Figure 14A). Several studies have described the 
accumulation of similar cytoplasmic aggregates such as lipofuscin vesicles, a molecular 
byproduct associated with replicative senescence and cellular aging.44 Lipofuscin 
molecules are an “aging pigment” and the byproduct of incomplete lysosomal 
degradation of damaged mitochondria. These observations lead us to investigate the 
induction of senescence in PC3+p53 (wild-type and mutant) in the presence and absence 
of ID4. A decrease in senescence associated betagalactosidase (SA-βgal) staining upon 
ID4 silencing suggested that loss of ID4 expression in PC3 cells upon overexpression of 
p53 (wild-type and mutant p53) down-regulated senescence at a higher frequency than 
transfected PC3 cells with endogenous ID4 (Figure 14A). The number of cells with 
strong (High) and those with light (Low-Moderate) blue staining were quantitated. The 
results summarized in (Figure 14 B) demonstrated a significant increase in the number of 
cells with SA-βgal staining in PC3 with endogenous ID4 (wild-type and mutant p53) (wt-
p53- 81, 2.3%, Moderate and 17, 0.9% High) (PL-29, 4.0%, Low, 66, 8.0%, High) (VF- 
65, 0.9%, Low, 25, 4.0%, Moderate, 8, 0.07%, High) (VFPL- 79,6.3%, None, 20, 1.0%, 
Low) as compared to silencing of ID4 (wt-p53- 44, 1.3% , Low, 60, 15%, Moderate) (PL- 
8,2.3%, None, 78, 13%, Low, 12, 2.5%, Moderate) (VF- 4, 0.9%, None, 88, 10.2%, Low, 






none of the PC3 (wild-type and mutant p53) –ID4 cells demonstrated High SA-βgal 
staining. Senescence in normal cells is associated with a flattened, enlarged morphology 
with >2 fold increase in cellular diameter compared to non-senescent cells.44 Over 60% 
of PC3 (wild-type and mutant p53) cells stained positive for the SA-βgal and ~20% of 
those cells appeared to have flattened morphology (Figure 14A) suggesting cyto-
architectural changes in PC3 (wild-type and mutant p53) cells.  
Several tumor suppressor genes are capable of inducing senescence through 
inhibition of the cell cycle by inducing a G1 arrest via either p21 [34], p27 [35] or p16 
and subsequently inhibiting the CDK2 dependent phosphorylation of the RB protein. 
However, PC3 cells have a highly deregulated cell cycle with a frame shift deletion 
mutation in the p53 gene, the key regulators of cell cycle and senescent pathways [36]. 
Our results demonstrate an increase in senescence in an ID4 dependent manner in 
PC3 (wild-type and mutant p53) cells. These results prompted us to investigate the 
underlying molecular mechanisms such as the influence of ID4 on regulatory 
mechanisms of p53 (MDM2, p14ARF); p53 DNA-binding and transcriptional activation; 
and a mechanism (acetylation) by which ID4 may influence mutant p53 to regain wild-
type biological activity. 
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Figure 14. ID4 promotes p53-mediated senescence. (A) ID4 promotes senescence in PC3 cells with 
overexpressed wild type and mutant p53. The cells (PC3+p53 and mutant p53) cells were stained with SA-
b-galactosidase. (B, C) The blue nuclei due to SA-bgalactosidase staining were counted in 15 randomly 
selected fields and expressed as mean+SEM. The flattened nuclei with intense blue staining were classified 
as cells with High senescence and smaller light blue nuclei were counted as cells with low-moderate 
senescence.                       
 
4.5 ID4 Regulates p53 Regulatory Mechanisms: p14ARF-MDM2 Interaction 
In the PC3+p53 (wild-type and mutant) (+/-) ID4 cellular model total MDM2 
protein was first immuno-precipitated and then immuno-blotted with p14ARF antibody 
from all cell lines.  Increased p14ARF was observed in PC3 cells with stably 
overexpressed wild type and mutant p53 as compared to PC3 cells transfected in the same 






the cell and directly interacts with MDM2 to regulate p53 biological activity.117a 
Moreover, when we immuno-blotted for p53 we saw decreased expression as compared  
to PC3 cells where ID4shRNA was used. This result suggested that ID4 promoted the 
sequester of MDM2 via p14ARF allowing p53 activation. In contrast, immuno-blot for 
p53 in the absence of ID4 (ID4shRNA). An increase in p53 expression was observed 
suggesting that MDM2 was still bound to p53. These results suggested that p53 may be 
targeted for degradation by its E3 ubitiquin ligase MDM2 and hence not functional 
(Figure 15).  These results provided evidence that ID4 promotes interaction between 
MDM2 and p14ARF one of the most common regulatory mechanisms of p53.117a   
 
Figure 15. ID4 regulates p53 via p14ARF and MDM2 interaction. (A) MDM2, immuno-precipitated from 
stable cell lines harboring overexpressed wild type and mutant p53 in the presence and absence of ID4 was 
blotted with antibodies against p14ARF and p53. 
 
4.6 ID4 Restores Mutant p53 DNA Binding and Transcriptional Activity 
An electrophoretic shift assay (EMSA) with canonical p53 DNA response 
element was used to determine the DNA binding ability of wild-type (LNCaP+NS) and 
mutant p53 (DU145). LNCaP+NS cells with wild-type p53 resulted in a gel shift (Figure 







LNCaP+NS cells possibly due to lower expression of wild-type p53 (Figures 16A). A 
distinct gel shift was observed in the presence of DU145+ID4 nuclear extracts, but no gel 
shift was observed with DU145 nuclear extracts suggesting that mutant p53 in the 
absence of ID4 lacks DNA binding activity. Increased p53 DNA binding activity using 
p53 response element immobilized on a 96 well plate followed by detection with p53 
specific antibody was also observed in LNCaP+NS and DU145+ID4 that was 
significantly higher as compared to LNCaP-ID4 and DU145 cells respectively (Figure 
16B).  In a functional transcriptional assay using a p53 response element (wt-p53RE) 
luciferase reporter plasmid, the relative p53 luciferase activity decreased significantly in 
LNCaP-ID4 cells as compared to LNCaP+NS cells (normalized to 1, Figure 16C), which 
is consistent with the expression of p53 in these cell lines.  Surprisingly, mutant p53 in 
DU145+ID4 cells demonstrated high luciferase activity as compared to DU145 
(normalized to 1, wt-p53RE). The mutant p53 luciferase plasmid (mt-p53RE) used as a 
negative control, as expected, did not result in luciferase activity.  In context of using 
LNCaP+NS as a positive control, our results strongly suggested that mut-p53 gains DNA 
binding and transcriptional activity in the presence of ID4 that is in part independent of 
its expression level.  Silencing of p53 through siRNA was used to further clarify the role 
of mutant p53 in DU145.  However, siRNA based p53 silencing led to massive apoptosis 
in DU145.225   
Real time quantitative PCR analysis on Chromatin immuno-precipitated (ChIP) 
with p53 antibody demonstrated the binding of wt-p53 to its respective response elements 






cells.  The decreased p53 expression in LNCaP-ID4 correlated with decreased binding to 
its respective promoter elements on BAX, p21 and PUMA promoters (P<0.001) (Figures 
16 E-F). As anticipated, in DU145 no significant binding of mutant p53 was observed on 
p21, PUMA and BAX promoters (Figures 16E-F).  However, in DU145+ID4 cells, a 
significant increase in the binding of mutant p53 as compared to DU145 was observed on 
BAX, p21 and PUMA promoters (Figures 16E-F).  
These observations lead us to investigate whether wild-type and mutant p53 in 
PC3 cells would also have the ability to regain DNA binding and transcriptional activity 
in an ID4 dependent manner. We used a p53 DNA binding activity assay that utilized 
nuclear extracts from our PC3 system We found increased p53 DNA binding activity 
using p53 response element immobilized on a 96 well plate followed by detection with 
p53 specific antibody in the PC3+p53 (wild-type and mutant p53) in the presence of ID4 
as compared the ID4 silencing model in PC3 cells where we observed a significant 
decrease in p53-DNA binding. (Figure 17A).  In a functional transcriptional assay using a 
p53 response element (wt-p53RE) luciferase reporter plasmid, the relative p53 luciferase 
activity decreased significantly in PC3+p53 (wild-type and mutant) upon ID4 silencing in 
cells as compared to PC3+p53 (wild-type and mutant) cells with endogenous ID4 
(normalized to 1, Figure 17B,C).  Surprisingly, mutant p53 (DU145 p53 mutant P223L 
and V274F) as well as hot spot mutants (R175H and R273H) overexpressed in cells 
demonstrated moderately high luciferase activity as compared to wild-type p53 
overexpressed in PC3 cells (normalized to 1, wt-p53RE).  The mutant p53 luciferase 






activity (Figure 17D,E).  In context of using PC3+wtp53 as a positive control, our results 
strongly suggested that mutant p53 gains DNA binding and transcriptional activity in the 









                                             
Figure 16. ID4 promotes DNA binding and transcriptional activity of wild type and mutant p53 in LNCaP 
and DU145 cells. A. EMSA with p53 consensus DNA binding response element with nuclear extracts from 
LNCaP (L), LNCaP-ID4 (L-ID4), DU145 (D), DU145+ID4 (D+ID4) and PC3 cells.  Nuclear extracts from 
PC3 cells, null for p53 and LNCaP cells with wild type p53 were used as negative and positive controls 
respectively.  Excess unlabeled (EU) p53 response element was used to monitor non-specific binding. B. 
Quantitative p53 DNA binding in a sandwich ELISA based system.  p53 was captured by double stranded 
oligonucleotide with p53 response element immobilized on a 96 well plate. The captured p53 was detected 
using p53 antibody by measuring the intensity at 450nm using HRP coupled secondary antibody.  C. The 
p53 transcriptional activity as determined by transiently transfecting cell lines as indicated above with p53 
response element driven luciferase reported plasmid (wt-p53RE).  The data is normalized to Renilla 
luciferase.  The mutant p53 luciferase reporter plasmid was used as a negative control (mt-p53RE).  The 
p53-luciferase reporter activity in LNCaP-ID4 (L-ID4) was normalized to LNCaP (L) and that of 
DU145+ID4 (D+ID4) with DU145 (D).  The data from 3 different experiments in triplicate is expressed as 
mean+SEM (*: P<0.001). D, E and F. Chromatin immuno-precipitation assay demonstrating the binding of 
p53 to its respective response element in the BAX (D), p21 (E) and PUMA (F) promoters.  The data is 
expressed as percent input is mean+SEM of three experiments in triplicate (a: between L and L-id4 and b: 













Figure 17. ID4 promotes DNA binding and transcriptional activity of wild type and mutant p53 in PC3 
cells. (A) Quantitative p53 DNA binding in a sandwich ELISA based system.  p53 was captured by double 
stranded oligonucleotide with p53 response element immobilized on a 96 well plate. The captured p53 was 
detected using p53 antibody by measuring the intensity at 450nm using HRP coupled secondary antibody in 
PC3 cells with overexpressed wild type and mutant p53 (+/-) ID4. (B-C) The p53 transcriptional activity as 
determined by transiently transfecting cell lines as indicated above with p53 response element driven 
luciferase reported plasmid (wt-p53RE).  The data is normalized to Renilla luciferase. (D-E)  The mutant 
p53 luciferase reporter plasmid was used as a negative control (mt-p53RE).  The p53-luciferase reporter 
activity in PC3+wtp53 and mutant p53 was normalized to PC3 and compared to PC3+wtp53 and mutant 








4.7 ID4 Recruits CBP/p300 to Promote p53 Acetylation 
Acetylation, independent of phosphorylation status promotes p53 stabilization and 
transcriptional activity but de-stabilizes its interaction with MDM2.101b Recent studies 
have also shown that acetylation of some mutant forms of p53 can restore the DNA 
binding activity.6c These studies led us to explore whether ID4 promotes acetylation of 
mutant p53 in DU145+ID4 cells. The total p53 protein was first immuno-precipitated and 
then immuno-blotted with acetylated lysine antibody. Increased global p53 lysine 
acetylation was observed in DU145+ID4 and LNCaP+NS cells as compared to LNCaP-
ID4 and DU145 cells. In p53, K320 is acetylated by PCAF and promotes p53-mediated 
activation of cell cycle arrest genes such as p21.226 In contrast, acetylation of K373 leads 
to hyper-phosphorylation of p53 NH2-terminal residues and enhances the interaction with 
promoters for which p53 possesses low DNA binding affinity, such as those contained in 
pro-apoptotic genes, BAX and PUMA.226 The results shown in (Figure 17A) 
demonstrated a significant increase in K373 acetylation in DU145+ID4 cells whereas no 
significant change was observed between LNCaP+NS and LNCaP-ID4 cells.  The K320 
expression was also significantly higher in DU145+ID4 and LNCaP+NS cells as 
compared to DU145 and LNCaP-ID4 cells.  These results provided evidence that ID4 is 
involved in promoting acetylation of specific residues in wild-type and mutant p53 that 
promotes its binding to respective response elements.  The increased K320 acetylation in 
DU145+ID4 cells clearly is consistent with the study by Parez et al.6c in which the 
authors demonstrated acetylation at this specific residue restores mutant p53 biological 






acetylated K373 in DU145+ID4 cells.  Acetylation at K373 is CBP/P300 dependent.227 
We hypothesized that if CBP/p300 is involved in K373 acetylation than it could co-
precipitate with p53. Our results demonstrated that indeed mutant p53 is physically 
associated with CBP/P300 at significantly higher levels than mutant p53 from DU145 
cells alone (Figure 18A).  These results led us to propose a model whereby, ID4 could 
recruit or promote the assembly of CBP/P300 and p53.  Immuno-precipitation with ID4 
and blotting with p53 demonstrated the presence of p53 in this complex in DU145+ID4 
and LNCaP+NS cells but not in DU145 and LNCaP-ID4 cells suggesting that ID4 
directly associates with p53 (Figure 18A).  These results consolidated our hypothesis that 
ID4 promotes the recruitment of CBP/p300 on p53 to promote acetylation and restore its 
biology. 
Moreover, we also investigated the acetylation profile used in the previous study 
via a histological examination of prostate xenografts using  (+/-) ID4 model system. 
LNCaP+NS, LNCaP -ID4, DU145, and DU145+ID4 cells were subcutaneously injected 
into the flanks of non-castrated nude male mice. Increased expression of Global lysine 
acetylation, acetylated lysine 320 and 373 in xenografts of LNCaP +NS and DU145+ID4 
were observed (Figure 18B). Tumors obtained from LNCaP-ID4 and DU145 xenografts 
saw significant decrease in acetylation markers (lysine 320 and 373) in the absence of 
ID4 (Figure 17B) Also, we observed modulation of total p53 in an ID4 dependent manner 
in prostate xenografts (Figure 18B). Upon ID4 silencing we observed decrease in total 
p53 expression as compared to LNCaP+NS and DU145 xenograft tissue (Figure 18B). To 






cellular death. The degree of apoptosis by TUNEL assay in the xenografts was used to 
understand the mechanism of tumor regression in response to various treatments. 
Representative examples of apoptosis at the conclusion of the experiments are shown in 
Figure 18C. The apoptotic index (no. of apoptotic nuclei/ total number of nuclei counted 
in 5 random fields) clearly suggested a significant increase in apoptosis in xenografts in 
LNCaP and DU145+ID4 as compared to LNCaP-ID4 and DU145. The increase in the 
number of apoptotic nuclei (dark brown) in LNCaP and DU145+ID4 groups as compared 
to LNCaP-ID4 and DU145, control is clearly visible in the images. We observed an 
increase in TUNEL in ID4 positive xenografts and compared to ID4 negative xenografts 
where we observed decrease in TUNEL staining indicating less apoptosis (Figure 18C). 
This result was consistent with our findings in our in vitro studies and correlated well 
with our acetylation profile (+/-) ID4. 
To further elucidate the mechanism of activation of mutant p53 to wild-type 
function, we investigated whether ID4 could promote a similar acetylation profile in the 
highly metastatic cell line PC3 as shown in LNCaP+NS and DU145+ID4 xenografts 
through immunohistological studies. The total p53 protein was first immuno-precipitated 
and then immuno-blotted with acetylated lysine antibody. Increased global p53 lysine 
acetylation was observed in DU145+ID4 and LNCaP+NS cells as compared to LNCaP-
ID4 and DU145 cells. The results shown in Figure 18D demonstrated a significant 
increase in global p53 acetylated lysine and K373 acetylation in PC3+p53 (wild type and 
mutant) cells whereas there was a significant decrease observed in both global p53 lysine 






study the effects of p53 aceytlation and deacytlation (acetyl-mimics: K320Q/R and 
K373Q/R) via the study of site-specific residues critical to the regulation of p53’s activity 
(Figure 19A). By overexpressing a collection of p53-R175H acetylation-mimic mutants 
in PC3 cells, we show that specific acetylation at K373, and to a lesser extent at K320, 
are sufficient for inducing p53 target gene dependent transactivation apoptosis and 
restoration of DNA-binding capabilities. Interestingly, we show that the inhibitory effect 
of deacetylation/non-acetylation (373R and 320R) has on p53 induced apoptosis and 
DNA-binding capability seemingly disrupting the global transcriptional program of p53 
by decreasing these activities (Figures 19B-C). Moreover, we find that ID4 was able to 
preferentially modulate apoptosis and DNA-binding capabilities at higher rate via acetyl-
mimic K373Q as compared to K320Q suggesting the K373 is most critical for ID4 
dependent p53 acetylation. Remarkably, our study reveals that a single lysine, K373 
and/or K320, in the c-terminal region of p53 can be acetylated to provide mutant forms of 
p53 DNA-binding and apoptotic capabilities. We however did observe the K320R and 
K373R (deacytlation mimics) mutants showed some relative luciferase activity as well as 
apoptosis, although not significant compared to K320Q and K373Q, respectively. 
Interestingly, Liu et al. reported activation of downstream target a p21-thymidine kinase 
construct was modest (15%) with deacytlation mimics; this result might have been due to 
the presence of two flanking lysines (K319 and K321), one of which might be an optional 
binding site for PCAF3, which could provide justification of similar apoptotic activity and 
luciferase activity we observed as well with both K320 and K373. Flanking lysines may 






further consolidate our hypothesis that ID4 acts a tumor suppressor via p53 by promoting 
acetylation of mutant p53 restoration to its wild-type biological activity.  
 
 
     
 
  
Figure 18. Acetylation of p53 and interaction with CBP/p300 and ID4. (A) p53, immuno-precipitated from 
cell lines LNCaP, LNCaP-ID4, DU145, and DU145+ID4 was blotted with antibodies against acetylated 
lysine (global), p53 acetylated at either K373 (Ac-373) or K320 (Ac-320), ID4, and CBP/ p300. (B) 
Representative images of xenografts from non-castrated nude male mice. Brown immunostainig of 
acetylated lysine (global), K373 (Ac-373), K320 (Ac-K320), and p53. (C) Representative images of 
xenografts from castrated SCID male mice, brown immunostaining of TUNEL indicating apoptosis. (D) 
p53, immuno-precipitated from cell lines PC3+wtp53 and mutant p53 was blotted with antibodies against 













Figure 19. ID4 promotes p53-R175H transcriptional activity and apoptosis. (A) p53-R175H Acetyl-mimic 
and deacetylation mimics constructs. (B) The p53 transcriptional activity as determined by transiently 
transfecting cell lines as indicated above with p53 response element driven luciferase reported plasmid (wt-
p53RE).  The data is normalized to Renilla luciferase. (D-E)  The mutant p53 luciferase reporter plasmid 
was used as a negative control (mt-p53RE).  The p53-luciferase reporter activity in PC3+mimics was 
normalized to PC3+NS and compared to PC3+mimics (-ID4) and PC3+shID4. (C) A significant increase in 
apoptosis (***: P<0.001) was observed in PC3+320Q+373Q and PC3+320R+373Q compared with 
PC3+320R+373R and PC3+320Q+373R. A significant decrease in apoptosis was observed in PC3 cells 












4.8 Molecular Dynamics: Studies of Mutations in p53 
The calculated energies based on the simulated annealing of the wild type and 
mutated core domain of p53 is shown in Table 4 (and Figure 20A). The total calculated 
energies (E) and normalized calculated energies per atom (Ea) were lower for wild type 
p53 (-19244 and -2.123 kcal/mol, respectively) as compared to the normalized energies 
per atom of hot spot mutants R175H and R273H (-2.0 kcal/mol), suggesting that the wild 
type p53 core domain was more thermodynamically stable as compared the hot spot 
mutants. In fact the Ea of the two temperature sensitive mutants P223L and V274F were 
essentially similar to the Ea of wild type suggesting similar thermodynamic stabilities.  
The same data (Table 4) plotted with wild-type set as a reference point clearly shows the 
magnitude of energy differences of the various core domain mutants (Figure 20B).  The 
Ea between the wild type and R175H and R273H have more difference in minimized 
energy to the wild type and with temperature sensitive mutants. 
 
Figure 20. (A) Difference in calculated energy between mutated proteins and the wild type based on results 






The stability of wild type p53 core domain is 6.0 kcal (1 kcal = 4.18 kJ)/mol at 
25°C and 9.8 kcal/mol at 10°C based on denaturation curves measured by differential 
scanning calorimetry/ spectroscopy 136 suggested that the p53 core domain is of moderate 
thermodynamic stability. Based on the above method the calculated equilibrium 
denaturation of p53 core domain at 10C was -2.97 kCal.mol-1.M-1.136 The calculated 
equilibrium denaturation at 10C of p53 mutants R175H, C242S, R248Q, R249S AND 
R273H WAS -2.59, -2.68, -2.91, -3.09 and -3.11 kCal.mol-1.M-1 respectively.136 Except 
R249S and R273H the equilibrium denaturation at 10C of p53 mutants was lower than 
the wild type, possibly because these mutants appear to part of the DNA binding domain.  
In contrast, the simulated normalized (per atom) calculated energy difference in our study 
at least for R273H is less than the respective wild type p53 core domain (Table 4 and 
Figure 20). Functionally the R273H is also a gain of function mutant found in majority of 
cancers.   
As compared to the temperature sensitive mutants, the effect of mutating an 
arginine is noticeable; changing an arginine to a histidine in two different positions shows 
the similarity of impact on minimized energy. Therefore, to understand whether the 
energy differences were specifically due to mutating arginine to histidine, we simulated 
the minimum energy calculations using another arginine mutation, R248Q.  R248Q is 
also a common mutation in many cancer types. Table V shows the minimized energy (Ea) 
of R248Q.  The energy difference between R248Q and wild type in context of R273H 
and R175H, shown in Figure 20B suggests that arginine residue places wild type p53 in 






mutations involve the arginine residue that alters the minimum energy of p53. Thus, 
irrespective of whether arginine mutations are structural (R175H) or functional 
(R273H),228 targeting an arginine residue appears to play a very significant role in 
thermodynamic stability of the p53 core domain.  
  We hypothesized that replacing arginine, the third heaviest residue in terms of 
molar mass, by a lighter residue may decrease thermodynamic stability. To study the 
effect of mutating a residue on the overall energy, we focused on linking the specific 
mutation to the overall bonded terms in energy.  As stated in the methods section, we 
used  a dimensionless quantity, to establish a correlation between the mutated and 
the wild type protein. Table VI summarizes  of results for p53 core domain mutants, 
which are also shown in Figure 21. 
 
     Figure 21. Approximation (μ) factor in correlation between  











Table 6. Calculation of , a Dimensionless Approximation Entity  












A comparison between approximation in Figure 21 and simulation in Figure 20A 
indicates that two different methods place mutated proteins in a similar context as 
compared to the wild type. Since  was a calculated approximation of mutants and its 2 
immediate neighbors with an approximation similar to that achieved by simulations in 
CHARRM, we therefore used a similar approximation for additional core domain p53 
mutants found in various cancers (Table VII). The results indicate that changes in 
potential energy depend not only on the molar mass of the target residue, but also to at 
least two other residues near the target residue. If two different mutations label the same 
residue position (e.g. R248Q & R248W), replacement by the lighter residue (Q) in molar 






replacement residues are the same (R175H & R273H), in the different positions, then 
changing the potential energy will be determined by the molar mass of near-neighbor 
residues. Mutations may present similar results (R248W & R282W) in our approximation 
if two near-neighbor residues are very similar or the same in molar masses. Every 
mutation with μ >1 in our results referred to a higher frequency in human cancer in p53. 
The rate of mutation in p53 in cancer references compares to 𝜇 factor (Table 8). Our 




Table 7. Results for More Mutations in p53 Based on our Approximation 
















Table 8. The Overall Frequency of Mutations in Human Cancer and 𝜇 Factor 
(Approximation). The minimum percentage of mutation in biology references matches to 




All the energy calculations described above are for minimized protein structure in 
the vacuum as an approximation and reduce noise. Since the proteins rarely exist in a 
dehydrated/ vacuum space, we therefore calculated the energies of the minimized 
structure of wild type and four mutated p53 core domains solvated in a box of water as 
large as the dimensions of each protein individually (block of water) (Figure 22A-E). The 
calculated energy in the vacuum and solvation for the wild type and mutant proteins was 
compared (Table 9).  The results suggested that there is no significant change in 








Figure 22. Wild-Type protein (A), mutated protein V274F (B), mutated protein R273H (C), mutated 
protein R175H (D) and mutated protein R175H (E) in a box of water individually. Each protein sets in a 


















5.1 Loss of ID4 Promotes Tumorigenecity of Prostate Cancer Cells  
 ID4 has been characterized as a tumor suppressor in many cancers, due to its 
promoter methylation in cancer tissues.  Previous studies from Carey et al., provided 
evidence in prostate cancer that ectopic ID4 induced apoptosis in prostate cancer cell 
lines DU145, while attenuating the cell cycle and proliferation.172a Since LNCaP cells 
express ID4, it was determined to be an ideal model in which to silence ID4.  Upon 
silencing of ID4, there was a decrease in apoptosis via increase in BAX and PUMA 
expression.  Upon silencing of ID4, there was an increase in proliferation of the LNCaP-
ID4 cells.  Studies have shown that there is inhibition of p27kip1 expression in prostate 
cancer, which results a proliferative phenotype.230 So the increased proliferation of 
LNCaP-ID4 cells may be due to decreased p27kip1 expression.  
5.2 ID4 Regulates Wild-type and Mut-p53 Biological Activity 
 The molecular mechanism by which wild type and mutant p53 may function has 
been reviewed extensively.4 These mechanisms include: p53 DNA-binding capabilities 
and transactivation of p53-dependent downstream targets. Mutant p53 function has been 
characterized by alterations in the DNA-binding ability of mutant p53, interaction of 






related to the regulation of gene expression.4 It is clear from our study herein that the 
effects of mutant p53 are strongly context dependent in regard to ID4. We provide 
evidence that ID4 regulates p53 regulatory mechanisms in PC3 cells where we have 
overexpressed wild type and mutant p53. MDM2 and p14ARF, key players in p53 
regulation of p53 are both modulated in the presence of ID4. Upon silencing of ID4 we 
observe increased co-elution of p53 as part of the MDM2-p14ARF-p53 complex, 
suggesting that MDM2 an E3 ubitiquin ligase for p53 is tightly bound to p53 and 
possibly targeting p53 for degradation. In this study we study both DU145 mutants 
(P223L and V274F) and hotpots mutants (R175H and R273H) DNA binding capabilities 
as well as transactivation potential. When wild type and mutant forms of p53 were 
overexpressed in PC3 cells we observed increased regulation of p53 downstream targets 
(p21, BAX, and PUMA) and upon ID4 silencing we observed decreased expression of all 
studied downstream targets of p53 in both DU145 mutant forms of p53 as well as hotspot 
mutants. We found that when wild type and mutant forms of p53 in the presence of ID4 
were overexpressed in PC3 cells we increase in p53-mediated apoptosis and senescence, 
suggesting that ID4 is playing a role in the biological activity of both wild type and 
mutant forms of p53.  
5.3 ID4 Dependent Acetylation Restores Mutant p53 Transcriptional Activity    
In the case of DU145 specific mutants (P223L and V274F) and hotspot mutants 
(R175H and R273H) we further establish that ID4 dependent acetylation is necessary for 
certain contact and structural mutant forms of p53 to gain sequence specific DNA-






and senescence, p53-dependent processes observed in DU145 cells in the presence of ID4 
further supports the role of ID4 in restoring the biological activity of mutant p53. Based 
upon our earlier observation, we speculate that ID4 dependent regulation of p53 is 
mediated via acetyltransferases such as CBP/p300 or by additional posttranslational 
modifications that occur in an acetylation dependent manner. It has been well established 
that several C-terminal lysines (evolutionarily conserved across species) of p53 (K370, 
K372, K373, K381, K382) are acetylated by CPB/p300.227 Acetylation of residues found 
in the C-terminal of p53 promotes an open conformation by inhibiting the ability of its C-
terminus to bind and occlude the DNA binding domain, thereby enhancing p53 
transcriptional activity.227,231 Inhibition of the C-terminal binding and occluding DNA via 
acetylation poses acetylation as a global mechanism of restoration of mutant p53.  
Studies have shown that acetylation of p53 by CBP/p300 is generally considered 
activating, but that is not always the case. The biological consequences of p53 acetylation 
by CBP/p300 may depend significantly on cellular context, such as cell type and/or 
transformation status (i.e., primary, immortalized or tumor-derived). For example, p300-
mediated acetylation of p53 in human cancer cell lines has been shown to be essential for 
p21 promoter transactivation and cell cycle arrest.231 Yet analyses of primary mouse 
embryo fibroblasts (MEFs) lacking CBP/p300 revealed those factors are not required for 
p53-mediated upregulation of p21 and MDM2 following DNA damage, although it is 
notable that the magnitude of their induction was reduced.232   
Cell type differences also influence the role of CBP/p300 in apoptosis. Most 






dependent apoptosis.233 Numerous cell types have been examined in the analyses, 
including primary MEFs and various human cancer lines. In contrast, loss of CBP/p300-
mediated p53 acetylation in HCT116 colorectal cells resulted in increased expression of 
PUMA and apoptosis following DNA damage, suggesting CBP/p300 expression 
normally suppresses p53-dependent apoptosis in those cells.234 Intriguingly, CBP/p300 
may act similarly in neurons. It was recently shown that p53 acetylation at K381 and 
K382 in neuronal cells specifically inhibits p53 binding to the PUMA promoter, 
preventing PUMA expression and DNA damage-induced cell death.235  
In our studies we used an acetyl-mimic model to study the effects of p53 
aceytlation and deacytlation (acetyl-mimics: K320Q/R and K373Q/R) by studyng of site-
specific residues critical to the regulation of p53’s activity. By overexpressing a 
collection of p53-R175H acetylation-mimic mutants in PC3 cells, we show that specific 
acetylation at K373, and to a lesser extent at K320, are sufficient for inducing p53 target 
gene dependent transactivation apoptosis and restoration of DNA-binding capabilities. 
Interestingly, we show that the inhibitory effect of deacetylation/non-acetylation (373R 
and 320R) has on p53 induced apoptosis and DNA-binding capability seemingly 
disrupting the global transcriptional program of p53 by decreasing these activities. 
Moreover, we find that ID4 may be preferentially modulating apoptosis and DNA-
binding capabilities at higher rate via acetyl-mimic K373Q as compared to K320Q 
suggesting the K373 is most critical for ID4 dependent p53 acetylation. Although not 
significant we did observe K320R and K373R (deacytlation mimics) relative luciferase 






Interestingly, Liu et al.122a found similar results when they reported activation of 
downstream target a p21-thymidine kinase construct was modest (15%) with deacytlation 
mimics; this result might have been due to the presence of two flanking lysines (K319 
and K321), one of which might be an optional binding site for PCAF, which could also 
provide an explanation of apoptotic activity and luciferase activity observed in our model 
with both K320R and K373R deacetylation mimics.  
It is also clear from our study herein that the effect of ID4 dependent acetylation 
of p53 has an affect on other known p53-mediated events in the cell. We provide 
evidence that ID4 regulates target genes of p53: BAX, PUMA, and p21, which are 
critical to p53-dependent cell cycle arrest and apoptotic event and modulation of MDM2 
and p14ARF, key players in p53 regulation. 
As discussed the main E3 ubiquitin ligase and negative regulator of p53 is 
MDM2, MDM2 is itself a transcriptional target of p53 that functions in a critical negative 
feedback loop to restrict p53 levels in non-stressed cells.207 Importantly, ubiquitin ligases 
negatively regulate the acetylation of p53 through several different mechanisms. First, 
MDM2 ubiquitylates the acetyltransferases CBP/p300, PCAF, and Tip60, which targets 
those proteins for degradation at the proteasome, thereby reducing their expression and 
ability to acetylate p53.231 Other studies have shown that C-terminal lysines of p53 
(K370, K372, K373, K381, K382) are competitively targeted for either acetylation or 
ubiquitylation as well.231   
Additional crosstalk between ubiquitylation and acetylation occurs because some 






ligase functions. Specifically, CBP/p300 can function as an E4 ubiquitin ligase for p53 
and cooperate with MDM2 to promote p53 polyubiquitylation.236 Also, interestingly it 
has been reported that changes in p53 phosphorylation can either facilitate or inhibit the 
binding of specific cofactors of p53, which can then block or promote acetylation. For 
example, N-terminal phosphorylation of p53 at S15, T18, S20 and/or S37 blocks MDM2 
association, with multisite phosphorylation more effectively than isolated 
phosphorylation events.231 Subsequent stabilization of p53 accompanied by reduced 
modification of lysines with competing ubiquitin fosters increased acetylation. 
Additionally, N-terminal p53 phosphorylation enhances binding to its acetyltransferases.  
The impact of other p53 post-translational modifications, such as methylation, 
sumoylation, and neddylation, on p53 acetylation and functions is generally not well 
defined. Methylation has been shown to counteract, cooperate with or not affect p53 
acetylation and activation depending on the site of modification and the study. p53 is 
methylated at K370 by Smyd2 (Set/MYND Domain-2), K372 by Set 7/9 (Su(var)3-9 and 
“Enhancer of zeste” protein 7/9), and K382 by Set8 (Su(var)3-9 and “Enhancer of zeste” 
protein 8).231 Methylation of K370 and K382 inhibits p53 DNA binding and 
transcriptional activity, and K382 methylation was shown to impair K382 acetylation.237  
There are currently not many investigators exploring p53 sumoylation and its 
impact on p53 acetylation. In fact, the functional consequences of sumoylation on p53 
activity in general remains unclear. Some early reports indicated that sumoylation 
promotes p53 recruitment into PML nuclear bodies and transcriptional activation.231 






occur on K370, K372, and K373 by MDM2 and on K320 and K321 by FBXO11 (F-box 
protein 11), and in each case it is associated with inhibition of p53-mediated 
transcription.238 The effect of p53 neddylation on its acetylation remains to be determined 
but it is predicted to interfere since both modifications occur on the same lysines.  
 The acetylation mechanism is nearly universal in nature and is suggestive from 
our studies that ID4 could promote acetylation of other known mutants as well; however, 
it is understood that sufficient structural flexibility of mutant forms of p53 are essential 
for recruitment of ID4 and macromolecular assembly of co-factor to p53, which could 
promote a similar acetylation pattern as shown in our studies (Figure 23). A profile of 
other known p53 hotspot mutants and study of their inherent structural flexibility in 
context of ID4 dependent acetylation is an area of great interest, which could provide a 
universal method of restoration of mutant p53 to that of wild type p53 function. 
   
 
Figure 23. ID4-p53 biological network. A representative image of ID4-p53 cross-talk. Green 








Studies including theoretical modeling of p53, and the p53 conformation changes 
induced by protein-protein and protein-ligand interactions, including peptide and small 
molecular inhibitors have significantly expanded our current understanding of the 
dynamic nature of p53 structure.133-134 While there have been several studies discussing 
the dynamic simulations of p53 in recent years, the dynamics and flexibility of mutation 
induced conformational changes of p53 have not been completely characterized or 
understood.    
5.4 Molecular Dynamic Simulation of Mut-p53 is Predictive and Correlative 
The current study evidenced herein confirmed that our method of molecular dynamic 
simulation of mutant forms of p53 can be predictive and correlative of the rate of 
mutation in human cancer.  Consequently, further investigations may be required before 
these findings can be generalized and applicable to diverse p53 mutants. Nonetheless, the 
R175H and R273H mutations are highly relevant to human cancers as well as many other 
hotspot mutations studied herein. A typical search of the IARC database establishes the 
prevalence of R175H and R273H as a somatic mutation in numerous different tumors and 
as a germline mutation in families with Li Fraumeni syndromes.132e 
The less frequently occurring p53 mutations (P223L and V274F used in this study) 
have been shown to essentially act as wild type at lower temperatures suggesting intrinsic 
flexibility.  It is therefore not surprising that the calculated energies of these two mutants 
are similar to the wild type p53. Thus taken together our studies reveal that p53’s intrinsic 






biological processes. This study via computational analysis aims to provide an 
understanding of p53 core domain structure and how manipulation of missense mutations 
found in p53 via simulation can be predictive of the rate of frequency of p53 mutations 
found in human cancer, thus giving insight to what therapeutic avenues could be most 








Even though p53 is one the best-studied genes as the result of 30 years extensive 
research, our comprehension and appreciation of its complexity in regulating many 
crucial biological processes are far from complete. It is indisputable that p53 suppresses 
tumorigenesis via the canonical pathway of inducing apoptosis and/or senescence and 
non-canonical pathways, some of which are still emerging.239 Conversely, p53 
dysfunction-induced tumorigenesis is mediated by loss of cell cycle arrest and apoptosis, 
as well as by compromising host immune surveillance.116, 240  
Since many p53 mutants are associated with a conformational change that hinders 
its DNA binding and transactivation capacity, it is rationalized that small molecules that 
revert the mutant p53 to its wild-type configuration will restore p53 function. Indeed, 
based on crystallographic structural and computational analyses, PRIMA-1 (p53 
reactivation and induction of massive apoptosis-1) and MIRA-3 (mutant p53 reactivation 
and induction of rapid apoptosis in vivo) were developed to convert mutant p53 and 
restore p53 function leading to effective activation of downstream apoptosis-inducing 






As in these previous studies, given the unique and the inherent conformational 
flexibility of p53 we also used computational analyses to study wild type and mutant p53 
that could eventually help to develop strategies to revert mutant p53 to its wild type 
configuration. The study presented herein also provided evidence that molecular dynamic 
simulation of mutant forms of p53 can be predictive and correlative of the rate of 
mutation in human cancers. In addition to our computational analysis of the core domain 
of wild type and mutant p53, we also investigated a novel physiological mechanism of 
restoration of mutant p53 via an hlh transcriptional regulator ID4.  
In many cancers, ID4 has been found to be hyper-methylated suppressing 
expression and function of ID4. Previous studies form our laboratory found that upon 
overexpression of ID4 in prostate cancer cell line DU145, in which ID4 is methylated 
there was an induction of senescence and apoptosis. Two genes primarily involved in 
senescence and apoptosis (RB and p16) are found to be non-functional in DU145 cells, 
whereas p53 is found to be mutated in this cell line,44 however when ID4 was 
overexpressed recovery of apoptosis and senescence was observed. The overlap in 
biological function of ID4 and p53 led us to investigate possible connections between 
both genes. From previous studies, we found that ID4 regulates the activity of wild type 
and mutant p53 via the assembly of a macromolecular complex involving CBP/p300 that 
resulted in acetylation of p53 at K373, a critical post-translational modification required 
for its biological activity.43 Furthermore, the study herein also found that ID4 could 
regulate wild type and mutant p53 when overexpressed in a highly metastatic cell line 






DU145 cells. Moreover, we observed that ID4 had a similar effect on hotspot p53-
mutants, most frequently found in cancers. Taken together, our present study finds that 
ID4 plays a pivotal role in modulation of acetylation and transactivation of p53 in context 
of both DU145 specific p53 mutants and hotspot mutants overexpressed in PC3 cells 
providing clear evidence that ID4 may serve as a physiological agent to restore p53 wild-
type function in a non-cell line/non-mutation specific manner given ID4 mediated mutant 
p53 restoration to wild type biological function in the PC3 cell line. While this data is 
intriguing, it is of great interest to determine if this phenomenon of p53 restoration via 
ID4 is effective in other organ systems as well as with a variety of other p53 mutations. 
Continued computational analysis along with further studies elucidating the mechanism 
of action will help to unravel the complex biological processes of ID4 and p53 in cancer. 
The strong anti-cancer effect of ID4 in prostate cancer and cross-talk with p53 will 
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